{"pageProps":{"data":{"blog":[{"categories":null,"seoNoIndex":false,"description":"Congratulations to David Heal, one of our Directors, on his recent promotion to Fellow of the American College of Neuropsychopharmacology (ACNP). ","_createdAt":"2025-01-19T16:03:51Z","seoEnabled":true,"_updatedAt":"2025-01-19T16:08:10Z","slug":{"current":"/news/david-heal-promoted-to-acnp-fellow","_type":"slug"},"_type":"article","_rev":"tiTonAuk6WGSOb8Zgb9rIT","image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"richText":[{"markDefs":[],"children":[{"_key":"ab04c4bec8440","_type":"span","marks":[],"text":"Congratulations to David Heal, one of our Directors, on his recent promotion to Fellow of the American College of Neuropsychopharmacology (ACNP). "}],"_type":"block","style":"normal","_key":"71c2cd2c4d1b"},{"_type":"block","style":"normal","_key":"1620bf05ceb7","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ACNP was founded in 1961 and is one of the oldest and most prestigious, international organisations of leading scientists focussed on disorders of the brain. Its members are widely recognised to be thought leaders in psychiatry and pharmacology. ","_key":"fb3b2e8f933f"}]},{"_key":"f67c71c4a82f","markDefs":[],"children":[{"_type":"span","marks":[],"text":"To reach Fellow status, members must have belonged to the College for at least five years and made substantial contributions to the ACNP and to the field of neuropsychopharmacology. The promotion to Fellow reflects Davids scientific achievements, his support for the next generation of young scientists, and his active participation in the annual meetings of the ACNP.","_key":"3b31c9985aa4"}],"_type":"block","style":"normal"}],"title":"David Heal promoted to Fellow of the ACNP","_id":"75e58760-ee95-487b-b82d-1c7dabda4e28","date":"2025-01-17"},{"title":"Join David Heal at the ACNP Annual Meeting in Phoenix, December 2024","_id":"0cb490e5-e558-44f7-9fed-4e136f22f2fc","_rev":"YUKNp3lJj5mV9vWyZXU9pR","date":"2024-12-03","image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"seoNoIndex":false,"seoEnabled":true,"richText":[{"markDefs":[],"children":[{"text":"One of our Directors, David Heal, will be participating in the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), to be held at the JW Marriott Desert Ridge Resort & Spa, Phoenix, Arizona, USA, 8th-11th December 2024.","_key":"87f547bd472b0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"a5c1e39f6b07"},{"style":"normal","_key":"605902175396","markDefs":[],"children":[{"_key":"74bda0dda6d3","_type":"span","marks":[],"text":"If you would like to see David at the ACNP to learn more about our services and research interests please get in touch or visit the following posters."}],"_type":"block"},{"children":[{"_type":"span","marks":["strong"],"text":"M215 Pharmacological Characterization of Centanafadine – Potential Implications for Efficacy and Safety in ADHD and Comorbid Psychiatric Disorders","_key":"94e7b2239dd80"}],"_type":"block","style":"normal","_key":"8e6bb8df9902","markDefs":[]},{"style":"normal","_key":"9a755e03e8d7","markDefs":[],"children":[{"text":"David Heal¹,², Sharon Smith¹, Jane Gosden¹, Reem Elbekai³","_key":"72293c9c791a0","_type":"span","marks":[]}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"¹DevelRx Ltd, BioCity, Nottingham, UK; ²Department of Life Sciences, University of Bath, Bath, UK; ³Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, Maryland, USA.","_key":"7e0d48001930"}],"_type":"block","style":"normal","_key":"65686b5ca7dc"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Poster Session I. Monday 9th December. 5.00-7.00 pm. Grand Canyon.","_key":"e500a7646f9d0"}],"_type":"block","style":"normal","_key":"18f9fb1fee8b"},{"children":[{"_type":"span","marks":["strong"],"text":"W228 New insights from electrophysiological and immunofluorescence experiments on the integration of kappa and mu opioid receptor signaling in the paraventricular thalamus","_key":"3dc66f77eb340"}],"_type":"block","style":"normal","_key":"804e6c5b8678","markDefs":[]},{"_type":"block","style":"normal","_key":"c309d2709721","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Eloise Kuijer¹,², Sarah Bailey¹, Sharon Smith³, Sue Wonnacott¹, Chris Bailey¹, David Heal¹,³","_key":"0f523d0caba10"}]},{"children":[{"_type":"span","marks":[],"text":"¹Department of Life Sciences, University of Bath, Bath, BA2 7AY, UK. ²Section of Sensory Science and Metabolism & Unit on Synaptic Modulation and Integration, National Institutes of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA. ³DevelRx Ltd, BioCity, Nottingham, NG1 1GF, UK.","_key":"db0e41ad39a80"}],"_type":"block","style":"normal","_key":"07336c936382","markDefs":[]},{"markDefs":[],"children":[{"_key":"293100fccba00","_type":"span","marks":[],"text":"Poster Session III. Wednesday 11th December. 5.00-7.00 pm. Grand Canyon."}],"_type":"block","style":"normal","_key":"3e4cecc20fdd"},{"children":[{"_type":"span","marks":[],"text":"","_key":"8ab1f09f626c"}],"_type":"block","style":"normal","_key":"c5c854c26119","markDefs":[]},{"style":"normal","_key":"c9057fea740d","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"ef0db8c3e0290"}],"_type":"block"}],"_createdAt":"2024-10-16T11:17:54Z","slug":{"current":"/news/join-david-heal-at-the-acnp-annual-meeting-in-phoenix-de","_type":"slug"},"_updatedAt":"2024-12-03T16:59:22Z","_type":"article","description":"David Heal will be participating in the 63rd Annual Meeting of the ACNP (American College of Neuropsychopharmacology) to be held at the JW Marriott Desert Ridge Resort & Spa, Phoenix, Arizona, USA, 8th-11th December 2024.","categories":null},{"categories":null,"date":"2024-08-27","_rev":"aE6OExzpuGGHZUQu8fn6DC","description":"Our latest publication evaluates the growing evidence from non-clinical and clinical studies for the anti-inflammatory and antioxidant effects of phytocannabinoids and assesses their potential to be efficacious treatments for neuroinflammatory disorders. ","_id":"e303c2db-d9a0-4e98-b1e9-be7e4fa8cd7f","seoEnabled":true,"seoNoIndex":false,"_updatedAt":"2024-08-27T16:16:02Z","slug":{"current":"/news/the-therapeutic-role-of-phytocannabinoids-in-neuroinflam","_type":"slug"},"richText":[{"markDefs":[],"children":[{"marks":[],"text":"The therapeutic potential of certain phytocannabinoids produced by the ","_key":"630e75c5abf20","_type":"span"},{"marks":["em"],"text":"Cannabis sativa","_key":"630e75c5abf21","_type":"span"},{"_type":"span","marks":[],"text":" plant is now well-recognised and has been proven by the regulatory approval for medical use of cannabidiol (Epidiolex®), chemically synthesized delta-9-tetrahydrocannabinol (Marinol® and Syndros®) and 1:1 delta-9-tetrahydrocannabinol/cannabidiol (Sativex®).","_key":"630e75c5abf22"}],"_type":"block","style":"normal","_key":"021cafb2e0d7"},{"_key":"160f78ab75ad","markDefs":[],"children":[{"_type":"span","marks":[],"text":"In our latest publication, we have evaluated the growing evidence from non-clinical and clinical studies for the anti-inflammatory and antioxidant effects of phytocannabinoids, discussed their proposed mode of action' and assessed the potential of phytocannabinoids and their synthetic analogues to be efficacious treatments for neuroinflammatory disorders.","_key":"9b563e589f9c0"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":[],"text":"The paper was written by Sharon Smith and David Heal of DevelRx and Ruarri Spurgeon and Taurri Spurgeon of Medicanna and EthicaCBD. It was recently published as part of a Special Issue ‘Natural Products in Neurotherapeutic Applications’ (Editor: Marcello Iriti) in Exploration of Neuroprotective Therapy.","_key":"ebe243220c110","_type":"span"}],"_type":"block","style":"normal","_key":"e625ebb381a5"},{"_key":"0098c2d17b05","markDefs":[],"children":[{"text":"The full details of the review are:","_key":"ffab089b11c40","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"22ddc61a861f","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Smith S, Spurgeon T, Spurgeon R, Heal D. Phytocannabinoids—Evaluation of their therapeutic role in neuroinflammation. Explor Neuroprot Ther. 2024;4:325–48. https://doi.org/10.37349/ent.2024.00087","_key":"f8758d1923f90"}]},{"_type":"block","style":"normal","_key":"f4834d4508f9","markDefs":[{"_type":"customLink","_key":"8a9c3a0ac279","customLink":{"external":"https://www.explorationpub.com/Journals/ent/Article/100487","blank":true,"_type":"customUrl"}}],"children":[{"_type":"span","marks":[],"text":"You can read the full text of the article ","_key":"71b808d519fa0"},{"_type":"span","marks":["8a9c3a0ac279"],"text":"here","_key":"623c5a636317"}]},{"_type":"block","style":"normal","_key":"016e1bfb60f9","markDefs":[],"children":[{"_type":"span","marks":[],"text":"If you are developing novel therapies from cannabinoids and would like to find out more about our experience in this area and how we can assist you please get in touch.","_key":"222df5b82b890"}]}],"image":{"_type":"image","alt":"DevelRx logo","asset":{"_type":"reference","_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png"}},"title":"The therapeutic role of phytocannabinoids in neuroinflammation","_createdAt":"2024-08-27T15:52:02Z","_type":"article"},{"slug":{"_type":"slug","current":"/news/meet-david-heal-at-the-safety-pharmacology-society-annua"},"_type":"article","_createdAt":"2024-08-20T10:12:14Z","description":"David Heal will be attending the Safety Pharmacology Society Annual Meeting to be held at the Town and Country Resort, San Diego, California, USA, 22nd to 25th September 2024. ","date":"2024-08-20","_id":"79e9ff0c-902e-4409-a26e-464ad0f7e093","image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"seoEnabled":true,"seoNoIndex":false,"_rev":"H2eNfRs8DF30uOfgcxfcjN","richText":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"David Heal will be attending the Safety Pharmacology Society Annual Meeting to be held at the Town and Country Resort, San Diego, California, USA, 22nd to 25th September 2024.","_key":"19b1e95decc20"}],"_type":"block","style":"normal","_key":"44182e0f603d"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Details of our posters are:","_key":"f5699765d7ff0"}],"_type":"block","style":"normal","_key":"6ec1a40fd00d"},{"style":"normal","_key":"4fb6a92d1c14","markDefs":[],"children":[{"_type":"span","marks":[],"text":"David Heal, Jane Gosden, Sharon Smith. ","_key":"dd9f83248cfc0"},{"_type":"span","marks":["strong"],"text":"Discriminating Evidence –","_key":"dd9f83248cfc1"},{"_type":"span","marks":[],"text":" ","_key":"dd9f83248cfc2"},{"marks":["strong"],"text":"Use and Misuse of the Drug Discrimination Test in Abuse Potential Assessments of Novel CNS Drugs.","_key":"dd9f83248cfc3","_type":"span"},{"_type":"span","marks":[],"text":" Poster Number 026-C.","_key":"dd9f83248cfc4"}],"_type":"block"},{"_type":"block","style":"normal","_key":"15ca82cd1de8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"David Heal, Jane Gosden, Sharon Smith. ","_key":"76268c1fd3880"},{"text":"Intravenous Self-administration – Valid Experimental Designs to Evaluate the Abuse Potential of Psychedelics, Entactogens and Drugs with Novel Mechanisms.","_key":"76268c1fd3881","_type":"span","marks":["strong"]},{"marks":[],"text":" Poster Number 027-C.","_key":"76268c1fd3882","_type":"span"}]},{"children":[{"text":"Poster presentation times are: 23rd September 2024. Poster Session 1. 3.00-3.45 pm. 24th September 2024. Poster Session 2. 9.15-10.00 am. Golden State Ballroom.","_key":"02623beebee70","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"acc68f11eacd","markDefs":[]},{"_type":"block","style":"normal","_key":"2ba15f6ffec7","markDefs":[],"children":[{"_type":"span","marks":[],"text":"David will also be describing the refinements to IVSA methodology required to test the new generation of CNS drugs (Poster 027) as an oral communication (Oral Communications 2. CNS/Respiratory. 23rd September 2.00-2.15 pm. Town & Country Ballroom D).","_key":"f28ae791d55d0"}]},{"children":[{"_type":"span","marks":[],"text":"If you would like to see David at the Safety Pharmacology Society meeting please get in touch or visit our posters.","_key":"e905f780c2ba0"}],"_type":"block","style":"normal","_key":"2cf8e80d6a47","markDefs":[]},{"_key":"83d158e7be0b","markDefs":[],"children":[{"_type":"span","marks":[],"text":"If your company is based in San Diego and you would like to see David while he is in the area please contact us via inform@develrx.com","_key":"f7dd1d5ba0f60"}],"_type":"block","style":"normal"}],"title":"Meet David Heal at the Safety Pharmacology Society Annual Meeting, San Diego, September 2024 ","categories":null,"_updatedAt":"2024-08-20T10:12:14Z"},{"date":"2024-07-16","image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"richText":[{"style":"normal","_key":"9ce8b28b1ce6","markDefs":[],"children":[{"_type":"span","marks":[],"text":"DevelRx are pleased to announce a new PhD studentship with the University of Bristol. The student, Katie Kamenish, started in March 2024 and is studying the emotional and reinforcing properties of novel opioid ligands for the treatment of pain. DevelRx is providing financial support (50%) for the project as part of our commitment to research and to support the training and development of the next generation of scientists. The industrial supervisors are Professor David Heal and Sharon Smith from DevelRx. The academic supervisors are Professor Emma Robinson and Dr Emma Cahill, from the University of Bristol. The project involves a collaboration with Professor Stephen Husbands from the University of Bath who will provide the novel opioid ligands for testing and further academic support. ","_key":"9bbd9bac13500"}],"_type":"block"},{"_key":"fee2c8f1aae4","markDefs":[],"children":[{"text":"","_key":"b55a4930aa4f","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"children":[{"marks":[],"text":"We are very much looking forward to working with Katie and our academic collaborators on this exciting new project.","_key":"b37e404b281a","_type":"span"}],"_type":"block","style":"normal","_key":"6dc737d262de","markDefs":[]}],"_updatedAt":"2024-09-23T10:42:14Z","slug":{"current":"/news/new-phd-studentship-with-the-university-of-bristol","_type":"slug"},"seoNoIndex":false,"_rev":"kHe6Ehb4iScGOS2PwgfIAT","title":"New PhD studentship with the University of Bristol","_id":"3dab3585-a63e-4aee-9843-fbc1105c79d6","_type":"article","description":"DevelRx are pleased to announce a new PhD studentship with the University of Bristol. The student, Katie Kamenish, started in March 2024 and is studying the emotional and reinforcing properties of novel opioid ligands for the treatment of pain. ","seoEnabled":true,"_createdAt":"2024-07-17T10:17:42Z","categories":null},{"title":"Critical evaluation of the abuse and dependence and associated safety risks of cannabinoids","_rev":"yBF5Fw73w0TvxhsjcZUY0t","categories":null,"_id":"3b7b4513-4229-4c37-bbe3-f551c1e69ef9","description":"If you are developing novel cannabinoid-based drugs for therapeutic use you may be interested in our recent critical evaluation of the abuse and dependence and associated safety risks of botanically-derived and chemically-synthesized cannabinoid compounds. ","_createdAt":"2024-06-18T15:06:15Z","date":"2024-06-18","image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"slug":{"current":"/news/critical-evaluation-of-the-abuse-and-dependence-and-asso","_type":"slug"},"_type":"article","seoNoIndex":false,"seoEnabled":true,"richText":[{"_type":"block","style":"normal","_key":"df68cbeb244c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"If you are developing novel cannabinoid-based drugs for therapeutic use you may be interested in our recent critical evaluation of the abuse and dependence and associated safety risks of botanically-derived and chemically-synthesized cannabinoid compounds. ","_key":"8b3f32e1a4180"}]},{"_key":"c70d136227da","markDefs":[],"children":[{"marks":[],"text":"Our review brings together evidence from non-clinical and clinical sources to assess the safety risks associated with psychoactive and non-psychoactive cannabinoids derived from cannabis and a wide range of synthetic cannabinoids (which are mostly psychoactive). ","_key":"000dd8f9d038","_type":"span"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Our methodology includes comparing the profiles of the different cannabinoids in the package of studies required by regulatory authorities like the FDA and EMA for the safety pharmacology assessment of drugs for medical use in humans. Data from other drugs of abuse have been considered for comparison. ","_key":"f5bd00e46be3"}],"_type":"block","style":"normal","_key":"deb8a1f61fd5"},{"style":"normal","_key":"cdbcea9a902c","markDefs":[],"children":[{"_key":"e8c09005a8cb","_type":"span","marks":[],"text":"The full details of the publication are:"}],"_type":"block"},{"style":"normal","_key":"46205afcf4a4","markDefs":[],"children":[{"text":"Heal DJ, Gosden J, Smith SL. A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids. Front Psychiatry, 2024; 15:1322434. doi.org/10.3389/fpsyt.2024.1322434.","_key":"e5fb1ad6b75b0","_type":"span","marks":[]}],"_type":"block"},{"style":"normal","_key":"24a15aba96d0","markDefs":[{"_type":"customLink","_key":"2c5a56c51dca","customLink":{"_type":"customUrl","external":"https://doi.org/10.3389/fpsyt.2024.1322434","blank":true}}],"children":[{"_key":"e26eaa2e00360","_type":"span","marks":[],"text":"You can download the article to read our conclusions about the abuse and dependence risks of cannabis-derived psychoactive and non-psychoactive cannabinoids and potent synthetic cannabinoid (CB1/CB2) receptor agonists "},{"text":"here","_key":"455db323997f","_type":"span","marks":["2c5a56c51dca"]}],"_type":"block"}],"_updatedAt":"2024-06-18T15:06:15Z"},{"_rev":"rSEg0qdn7ObNwCMyW8CZ3Y","_type":"article","seoEnabled":true,"categories":null,"description":"One of the Directors of DevelRx, David Heal, will be participating in the 86th Annual Meeting of the College on Problems of Drug Dependence to be held at Fairmont The Queen Elizabeth Hotel in Montreal, Quebec, Canada, 15th-19th June, 2024.","image":{"alt":"DevelRx logo","asset":{"_type":"reference","_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png"},"_type":"image"},"richText":[{"style":"normal","_key":"bf28b77b6e20","markDefs":[],"children":[{"marks":[],"text":"One of the Directors of DevelRx, David Heal, will be participating in the 86th Annual Meeting of the College on Problems of Drug Dependence to be held at Fairmont The Queen Elizabeth Hotel in Montreal, Quebec, Canada, 15th-19th June, 2024.","_key":"c53f6c6bee820","_type":"span"}],"_type":"block"},{"_key":"d4f6a52fe1ea","markDefs":[],"children":[{"_type":"span","marks":[],"text":"We have two posters describing non-clinical studies to evaluate the abuse and dependence potential of the cholesterol-24-hydroxylase inhibitor, soticlestat, that is being developed by Takeda for the treatment of seizures in Dravet syndrome and Lennox-Gastaut syndrome. These posters are with Kristin Horn, Gvido Cebers and James Blank of Takeda Development Center Americas, Inc and Sharon Rowton of Labcorp.","_key":"cccf4a2f186d0"}],"_type":"block","style":"normal"},{"children":[{"_key":"ce614a89a5f50","_type":"span","marks":["strong"],"text":"T169. Evaluation of the Abuse Potential of the Cholesterol-24-Hydroxylase Inhibitor, Soticlestat, in Drug-Discrimination and Self-Administration Tests. "},{"_key":"ce614a89a5f51","_type":"span","marks":[],"text":"David Heal, Sharon Rowton, Sharon Smith, Jane Gosden, Kristin Horn, Gvido Cebers, James Blank. Tuesday 18th June 2024. 5:30 pm - 7 pm. Agora & Centre-Ville, Lobby Level"}],"_type":"block","style":"normal","_key":"06a60bf4690b","markDefs":[]},{"_type":"block","style":"normal","_key":"64ad8af21465","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"T171. Assessment of Withdrawal-Induced Physical Dependence in Rats after Administration of the Potent Cholesterol-24-Hydroxylase Inhibitor, Soticlestat. ","_key":"4a19d54529420"},{"_type":"span","marks":[],"text":"Sharon Rowton, David Heal, Sharon Smith, Jane Gosden, Kristin Horn, Gvido Cebers, James Blank. Tuesday 18th June 2024. 5:30 pm - 7 pm. Agora & Centre-Ville, Lobby Level","_key":"4a19d54529421"}]},{"_key":"cec476bc05e5","markDefs":[],"children":[{"text":"DevelRx also has a poster comparing the antinociceptive and aversive effects of the kappa opioid receptor agonists, nalfurafine and U50,488, with Eloise Kuijer, our PhD student with Chris Bailey, Sarah Bailey and Sue Wonnacott of the Department of Life Sciences, University of Bath.","_key":"876f46a094de0","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"children":[{"marks":["strong"],"text":"W58. Nalfurafine is Aversive at Analgesic Doses – Non-Clinical Evidence to Indicate It is Not an Atypical Kappa Opioid Receptor Agonist.","_key":"81131d44c3d30","_type":"span"},{"_type":"span","marks":[],"text":" Eloise Kuijer, Sarah Bailey, Sue Wonnacott, Chris Bailey, David Heal, Sharon Smith. Wednesday 19th June 2024. 2.15 pm – 3.45 pm. Agora & Centre-Ville, Lobby Level","_key":"81131d44c3d31"}],"_type":"block","style":"normal","_key":"428ee395a532","markDefs":[]},{"_key":"28e665112e1e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"David would be pleased to see you at any of the posters. If you would like a specific meeting with him at the CPDD to discuss how DevelRx can support the development of your novel centrally-acting compounds please get in touch.","_key":"db7d35f48d9f0"}],"_type":"block","style":"normal"}],"_createdAt":"2024-05-05T14:08:12Z","date":"2024-06-03","_id":"15ff7c21-a20a-4a79-9a4f-3822186a3b93","slug":{"current":"/news/meet-david-heal-at-the-cpdd-86th-annual-scientific-meeti","_type":"slug"},"_updatedAt":"2024-06-03T07:55:41Z","seoNoIndex":false,"title":"Meet David Heal at the CPDD 86th Annual Scientific Meeting, Montreal, Quebec, June 2024"},{"_createdAt":"2024-03-28T11:41:11Z","description":"David Heal has been accepted as an in-person participant at the European Medicines Agency (EMA) meeting ‘EMA multi-stakeholder workshop on psychedelics – Towards an EU regulatory framework’ to be held at the EMA, Amsterdam, The Netherlands, 16th-17th April 2024.","title":"EMA multi-stakeholder workshop on psychedelics – Towards an EU regulatory framework","seoNoIndex":false,"image":{"_type":"image","alt":"DevelRx logo","asset":{"_type":"reference","_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png"}},"date":"2024-03-28","_type":"article","richText":[{"children":[{"_type":"span","marks":[],"text":"David Heal has been accepted as an in-person participant at the European Medicines Agency (EMA) meeting ‘EMA multi-stakeholder workshop on psychedelics – Towards an EU regulatory framework’ to be held at the EMA, Amsterdam, The Netherlands, 16th-17th April 2024.","_key":"e21f19ca3cbe0"}],"_type":"block","style":"normal","_key":"1c0a70047a77","markDefs":[]},{"style":"normal","_key":"e35220cfe28e","markDefs":[],"children":[{"_key":"1c068b1086c10","_type":"span","marks":[],"text":"The workshop brings together patients and experts from the healthcare sector, academia, the pharmaceutical industry and regulatory bodies to discuss the opportunities and challenges in developing safe and effective psychedelics for the treatment of a variety of psychiatric conditions. The aim of the workshop is to provide a basis for the development of EU regulatory guidance on the therapeutic use of psychedelics."}],"_type":"block"},{"children":[{"_key":"69f0c99a264b0","_type":"span","marks":[],"text":"The meeting is by invitation only but will be broadcast live. For further details please click "},{"_type":"span","marks":["ace7ce739ad9"],"text":"here","_key":"744d024a49bb"},{"marks":[],"text":".","_key":"18e662c8ee0c","_type":"span"}],"_type":"block","style":"normal","_key":"c00f87b320ef","markDefs":[{"_key":"ace7ce739ad9","customLink":{"external":"https://www.ema.europa.eu/en/events/ema-multi-stakeholder-workshop-psychedelics-towards-eu-regulatory-framework","blank":true,"_type":"customUrl"},"_type":"customLink"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"DevelRx specialises in the evaluation of the abuse potential of novel psychedelics. If you are attending this workshop and would like to meet David to discuss our services please get in touch.","_key":"f92ef165ef000"}],"_type":"block","style":"normal","_key":"37e87cf2c021"},{"_key":"0924ac4f99d6","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"678cc9920180"}],"_type":"block","style":"normal"}],"seoEnabled":true,"slug":{"current":"/news/ema-multi-stakeholder-workshop-on-psychedelics-towards-a","_type":"slug"},"categories":null,"_id":"9318bf9b-9e75-4284-9b4e-41bafad2a2ba","_rev":"kv3DnWIcy05RCWtHY23soB","_updatedAt":"2024-03-28T17:18:54Z"},{"description":"We are pleased to announce that our latest review on the use of stimulant prodrugs to treat attention deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED) has recently been published.","_createdAt":"2023-10-26T14:53:09Z","image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"_rev":"bwjmyF8qb3kmUEGeGHFDSh","seoNoIndex":false,"_type":"article","richText":[{"_key":"3a77562655b4","markDefs":[{"_type":"customLink","_key":"575eea4e4a9a","customLink":{"_type":"customUrl","external":"https://www.sciencedirect.com/science/article/abs/pii/S1054358923000522","blank":true}}],"children":[{"_type":"span","marks":[],"text":"We are pleased to announce that our latest review on the use of stimulant prodrugs to treat attention deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED) has recently been published.\n\nHeal DJ, Gosden J, Smith SL. Chapter Nine - Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder. In: Pharmacological Advances in Central Nervous Stimulants.  Gnegy ME (Ed). Adv Pharmacol, Elsevier, 2024; 99: 251-286. https://doi.org/10.1016/bs.apha.2023.10.002.  ","_key":"a9fdbcd9805f0"},{"_type":"span","marks":["575eea4e4a9a"],"text":"Read more...","_key":"3da38b6b0aea"},{"_type":"span","marks":[],"text":"\n\nPlease get in touch if this topic is of particular interest to you.","_key":"c07d45d6c083"}],"_type":"block","style":"normal"}],"date":"2024-03-08","_id":"430d88ce-042a-4c44-a723-e3a96a96c64f","slug":{"current":"/news/the-role-of-stimulant-prodrugs-in-the-treatment-of-adhd-","_type":"slug"},"seoEnabled":true,"_updatedAt":"2024-03-10T15:59:33Z","title":"The role of stimulant prodrugs in the treatment of ADHD and binge-eating disorder","categories":null},{"_id":"70fe1007-e822-43e4-90d6-07d6cecf61bb","_type":"article","description":"David Heal and Eloise Kuijer, our PhD student with Chris Bailey, Sarah Bailey and Sue Wonnacott of the Department of Life Sciences, University of Bath, will be presenting posters at the 62nd Annual Meeting of the American College of Neuropsychopharmacology, 3rd to 6th December, 2023, to be held at JW Marriott Tampa Water Street, Tampa, Florida, USA. ","date":"2023-11-08","image":{"alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"},"_type":"image"},"title":"Join us at the Annual Meeting of the ACNP, Tampa, Florida, 3rd to 6th December 2023","richText":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"David Heal and Eloise Kuijer, our PhD student with Chris Bailey, Sarah Bailey and Sue Wonnacott of the Department of Life Sciences, University of Bath, will be presenting posters at the 62nd Annual Meeting of the American College of Neuropsychopharmacology, 3rd to 6th December, 2023, to be held at JW Marriott Tampa Water Street, Tampa, Florida, USA. Please visit the posters to learn more about our research interests.","_key":"3196bbfbe9880"}],"_type":"block","style":"normal","_key":"b52aa758555b"},{"_type":"block","style":"normal","_key":"01856425e530","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"bec05f6869400"}]},{"markDefs":[],"children":[{"_key":"ed91ca3da1420","_type":"span","marks":["strong"],"text":"M154. Kappa and Mu Opioid Receptors in the Paraventricular Thalamus Reveal Enigmatic Roles in Assimilation, Integration, and Processing of Aversive and Rewarding CNS Signals."},{"_key":"ed91ca3da1421","_type":"span","marks":[],"text":" Eloise Kuijer, Chris Bailey, Sarah Bailey, Sue Wonnacott, Sharon Smith & David Heal. Monday 4th December 2023. JW, Tampa Bay Ballroom. 5.00 pm -7.00 pm."}],"_type":"block","style":"normal","_key":"24b655f87be3"},{"children":[{"_type":"span","marks":[],"text":"","_key":"0aca0ae24a730"}],"_type":"block","style":"normal","_key":"759b5f18efeb","markDefs":[]},{"_key":"b0a0eb30b3e4","markDefs":[],"children":[{"_key":"f2dd2498ddb00","_type":"span","marks":["strong"],"text":"T179. Evidence to Show Nalfurafine is Aversive at Analgesic Doses Suggesting it is not an Atypical Kappa Opioid Receptor Agonist."},{"_type":"span","marks":[],"text":" David Heal, Eloise Kuijer, Sarah Bailey, Sue Wonnacott, Sharon Smith & Chris Bailey. Tuesday 5th December 2023. JW, Tampa Bay Ballroom. 5.00 pm -7.00 pm.","_key":"f2dd2498ddb01"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"55d84b4b4f8c0"}],"_type":"block","style":"normal","_key":"883c1a1b8caf"},{"children":[{"marks":[],"text":"If you would like a specific meeting with David to discuss how we can support the development of your centrally-acting drug candidates please contact ","_key":"6e8fdf7b0bf2","_type":"span"},{"_type":"span","marks":["4d262050e2f2"],"text":"inform@develrx.com","_key":"da2f1bf5a33e"},{"_type":"span","marks":[],"text":".","_key":"9941b96a1afe"}],"_type":"block","style":"normal","_key":"7980c2702922","markDefs":[{"_type":"customLink","_key":"4d262050e2f2","customLink":{"external":"mailto:inform@develrx.com","blank":false,"_type":"customUrl"}}]}],"seoEnabled":true,"categories":null,"_createdAt":"2023-11-08T15:31:30Z","slug":{"_type":"slug","current":"/news/join-us-at-the-annual-meeting-of-the-acnp-tampa-florida-"},"seoNoIndex":false,"_rev":"tCsgZg5ERtm4M1Y3R7dtEG","_updatedAt":"2023-11-08T15:44:51Z"},{"seoEnabled":true,"_createdAt":"2023-10-10T10:34:43Z","_id":"bb68be1f-dba8-4904-978c-feb549bcf690","date":"2023-10-09","_rev":"xG3JI1lVAA8jNI3DnVyPB3","slug":{"current":"/news/sharon-smith-joins-editorial-board-of-the-journal-of-psy","_type":"slug"},"image":{"alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"},"_type":"image"},"_type":"article","_updatedAt":"2023-10-10T10:34:43Z","seoNoIndex":false,"categories":null,"title":"Sharon Smith joins Editorial Board of the Journal of Psychopharmacology","description":"Congratulations to Sharon Smith, one of our Executive Directors, who has recently been voted onto the Editorial Board of the Journal of Psychopharmacology - a fully peer-reviewed, international journal publishing original scientific papers and reviews on preclinical and clinical psychopharmacology. ","richText":[{"_type":"block","style":"normal","_key":"8b336fcf0d68","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Congratulations to Sharon Smith, one of our Executive Directors, who has recently been voted onto the Editorial Board of the Journal of Psychopharmacology - a fully peer-reviewed, international journal publishing original scientific papers and reviews on preclinical and clinical psychopharmacology. Sharon has more than 25 years of research and development experience gained from working in pharmaceutical and biotech companies and contract research organisations. Her core expertise lies in the discovery and development of new drugs to treat psychiatric and neurological disorders. Sharon has worked extensively on the development of innovative experimental models to more accurately predict the abuse liability of novel compounds and to assess the therapeutic potential of new treatments for substance use disorders. Her invitation to join the Editorial Board of the Journal of Psychopharmacology reflects her extensive experience in preclinical psychopharmacology as exemplified by numerous publications in this area and by acting as co-editor of four Special Issues of Neuropharmacology.","_key":"8ae8a840fd190"}]}]},{"image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"_type":"article","_createdAt":"2023-08-29T09:31:53Z","seoEnabled":true,"_rev":"tCsgZg5ERtm4M1Y3R7e4El","title":"Advancements and Challenges in Abuse Potential Evaluation 2023","_id":"4ad09791-c2f9-446a-9859-b8be7910359f","slug":{"current":"/news/advancements-and-challenges-in-abuse-potential-evaluatio","_type":"slug"},"_updatedAt":"2023-11-08T15:53:40Z","richText":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"David Heal has been invited to speak at this meeting which has been organised by CCALC, the Cross-Company Abuse Liability Council. It will be held on 27-28th September 2023 at the Hilton Washington DC/Rockville Hotel and Executive Meeting Center.","_key":"7e45135ca21a0"}],"_type":"block","style":"normal","_key":"3473ca3b6718"},{"children":[{"_type":"span","marks":[],"text":"CCALC Conferences bring together representatives from the pharmaceutical industry, service providers, academia and the FDA to reach a consensus view on addressing new challenges in evaluation of the abuse potential and dependence of CNS-active drugs.","_key":"8bffa93f57920"}],"_type":"block","style":"normal","_key":"abc6ff6c27cf","markDefs":[]},{"_key":"8158f36a38c4","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The meeting this year includes a session on the preclinical and clinical assessment of the abuse liability of novel psychedelic drug-candidates.","_key":"299395c801740"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"David will be speaking and a panelist for the session ","_key":"bbf3633ab54f0"},{"_type":"span","marks":["strong"],"text":"‘Topic #4: Methodological Considerations for the Abuse Potential Evaluation of Psychedelics’","_key":"6531829c7abe"},{"_type":"span","marks":[],"text":" to be held during the afternoon of 27th September.","_key":"836b8770acab"}],"_type":"block","style":"normal","_key":"b535c8c3bb60"},{"children":[{"_type":"span","marks":[],"text":"The title of his presentation is : ","_key":"48cb8137b90f0"},{"_key":"c49758d8d590","_type":"span","marks":["strong"],"text":"‘Translationally valid experimental designs to evaluate the abuse potential of psychedelic drugs.’"}],"_type":"block","style":"normal","_key":"fa1f872fde0f","markDefs":[]},{"_type":"block","style":"normal","_key":"e66908767d49","markDefs":[],"children":[{"_type":"span","marks":[],"text":"David will be describing how we need to modify and refine non-clinical testing procedures to determine the risks to patients and society posed by the next generation of psychedelics.","_key":"1be202b206d20"}]},{"_key":"8cc792306b0c","markDefs":[{"_type":"customLink","_key":"5519329512e3","customLink":{"_type":"customUrl","external":"https://apdialogue2023.com/","blank":true}}],"children":[{"_type":"span","marks":[],"text":"His slides will be available after the meeting on the ","_key":"80d767ed75c40"},{"_type":"span","marks":["5519329512e3"],"text":"Cross-Company Abuse Liability Council website.","_key":"8e0a75219824"}],"_type":"block","style":"normal"},{"style":"normal","_key":"e973f0f7b268","markDefs":[],"children":[{"marks":[],"text":"If you are developing novel psychedelics for therapeutic use and would like more information about our experience and expertise in this area please get in touch. ","_key":"59621b7a293d","_type":"span"}],"_type":"block"}],"categories":null,"date":"2023-09-04","seoNoIndex":false,"description":"David Heal has been invited to speak at this meeting, organised by CCALC (Cross-Company Abuse Liability Council) and the FDA. It will be held on 27-28th September 2023 at the Hilton Washington DC Hotel in Rockville,  MD, USA."},{"seoNoIndex":false,"date":"2023-08-15","richText":[{"_key":"ecbde438fba1","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Drugs that influence noradrenergic neurotransmission have made an enormous contribution to pharmacotherapy in psychiatry. David Heal, one of our Directors, and Clare Stanford, Department of Neuroscience, Physiology and Pharmacology, University College London, have recently written a chapter in the Handbook of Experimental Pharmacology describing how direct or indirect modulation of the function of specific adrenoceptor subtypes contributes to the efficacy and safety of drugs for the treatment of various psychiatric disorders including schizophrenia, depression, anxiety, attention-deficit hyperactivity disorder, binge-eating disorder and substance use disorder. This article is now available online.","_key":"fa9674d0069e0"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"text":"Stanford, S.C., Heal, D.J. (2023). Adrenoceptors: A Focus on Psychiatric Disorders and Their Treatments. In: Handbook of Experimental Pharmacology. Springer, Berlin, Heidelberg.","_key":"6a7de01bee780","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"b6209426fa54"},{"_key":"d25129210328","markDefs":[{"_key":"589014448849","customLink":{"_type":"customUrl","external":"https://link.springer.com/chapter/10.1007/164_2023_675","blank":true},"_type":"customLink"}],"children":[{"text":"Please click ","_key":"ef2c4e32425d0","_type":"span","marks":[]},{"_type":"span","marks":["589014448849"],"text":"here","_key":"670305f360f0"},{"_type":"span","marks":[],"text":" for further information or contact us if this topic is of particular interest to you.","_key":"4da8345bd451"}],"_type":"block","style":"normal"}],"categories":null,"_updatedAt":"2023-08-15T15:06:50Z","_rev":"NWOt1I2xWP7xm05A83R5xg","_createdAt":"2023-08-15T11:11:35Z","slug":{"current":"/news/focus-on-the-role-of-adrenoceptors-in-the-causes-and-tre","_type":"slug"},"_id":"34f1fb51-92da-41de-a723-556cf4991b86","image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"_type":"article","seoEnabled":true,"description":"David Heal, one of our Directors, and Clare Stanford, University College London, have written a chapter in the Handbook of Experimental Pharmacology describing how modulation of the function of specific adrenoceptor subtypes contributes to the efficacy and safety of drugs for the treatment of psychiatric disorders.","title":"Focus on the role of adrenoceptors in the causes and treatment of psychiatric disorders"},{"seoEnabled":true,"_createdAt":"2023-07-24T15:00:56Z","description":"It provides a comprehensive overview of the extraordinary progress in basic and clinical research on psychedelic drugs made during the past five years.","date":"2023-07-24","_id":"9aed85fc-6baf-4116-a8e1-7a9dbbf67b51","seoNoIndex":false,"_type":"article","categories":null,"image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"_rev":"XYs5CWqIz9KsYqFMh72DEt","title":"The Special Issue of Neuropharmacology ‘Psilocybin Research’ is now out in print","slug":{"current":"/news/the-special-issue-of-neuropharmacology-'psilocybin-resea","_type":"slug"},"richText":[{"_key":"af9e4de1a9d1","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The Special Issue of Neuropharmacology ‘Psilocybin Research’ is now out in print. It provides a comprehensive overview of the extraordinary progress in basic and clinical research on psychedelic drugs made during the past five years (since publication of the previous Special Issue of Neuropharmacology ‘Psychedelics: New Doors, Altered Perceptions’ in 2018).","_key":"25871793fd1e0"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"db53ca07c9b9","markDefs":[],"children":[{"marks":[],"text":"This Special Issue is largely based on the seminar series on psilocybin, organized by the National Institutes of Health (NIH), USA from April to June 2021, complemented by invited reviews from eminent workers on psychedelic drugs. Contributions are from world leading scientists, medical practitioners, clinical psychologists and oncologists, and experts from additional disciplines of patient advocacy, law, government science policy and regulatory policy. Topics covered in the Special Issue include policy, ethics and legal issues, regulatory aspects of drug development, basic research, clinical research and the potential therapeutic use of psilocybin in major depressive disorder, treatment resistant depression, cancer-related anxiety and depression, anorexia, post-traumatic stress disorder, substance use disorders and chronic pain.","_key":"9fb82f0f06110","_type":"span"}]},{"style":"normal","_key":"e3c345f4bd02","markDefs":[],"children":[{"_key":"73cb90bf527b0","_type":"span","marks":[],"text":"The reviews in this Special Issue of Neuropharmacology critically appraise the advances and challenges for psychedelic drug development providing a valuable resource for all workers in the pharmaceutical industry striving to bring new psychedelic drugs into mainstream therapeutic use. Although the strategies discussed are based on evaluation of the drugs in the USA, approval of the clinical use of psychedelics by the FDA will inevitably have global implications."}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"The Special Issue of Neuropharmacology on psychedelic drugs was edited by two of our experts, David Heal and Sharon Smith, and by Jack Henningfield (Pinney Associates, Bethesda, MD, USA; John Hopkins University School of Medicine, Baltimore, MD, USA) and Sean Belouin (United States Public Health Service, Germantown, MD, USA; Substance Abuse and Mental Health Services Administration, Rockville, MD, USA and Pain and Palliative Care, NIH Clinical Research Center, Bethesda, MD, USA). ","_key":"435f11800f110"}],"_type":"block","style":"normal","_key":"e772a80e6ff7","markDefs":[]},{"_type":"block","style":"normal","_key":"47c565e44524","markDefs":[{"customLink":{"external":"https://www.sciencedirect.com/journal/neuropharmacology/special-issue/10TFVWPHZCS","blank":true,"_type":"customUrl"},"_type":"customLink","_key":"7ee0af1f341c"}],"children":[{"_type":"span","marks":[],"text":"Details of the contents of the Special Issue of Neuropharmacology ‘Psilocybin Research’ can be found ","_key":"b552a71820700"},{"_key":"472eee35624d","_type":"span","marks":["7ee0af1f341c"],"text":"here"},{"_type":"span","marks":[],"text":". Articles are available online via open access.","_key":"d5ff90a8ad21"}]},{"_key":"0df0658f7bee","markDefs":[],"children":[{"_key":"b976357ab1900","_type":"span","marks":[],"text":"Contributions to the journal from DevelRx are:"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"565bc32f03bc","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Psychedelics: Threshold of a Therapeutic Revolution. DJ Heal, SL Smith, SJ Belouin, JE Henningfield. Article 109610. (Editorial)","_key":"dafc9f884ecd0"}]},{"_type":"block","style":"normal","_key":"70a673a326bf","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines. DJ Heal, J Gosden, SL Smith, CK Atterwill. Article 109375 (Review)","_key":"025c3b74c8a20"}]},{"_type":"block","style":"normal","_key":"f715d2874737","markDefs":[],"children":[{"text":"Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. JE Henningfield, MA Coe, RR Griffiths, SJ Belouin, A Berger, AR Coker, SD Comer, DJ Heal, PS Hendricks, CD Nichols, F Sapienza, FJ Vocci, FZ Zia. Article 109220 (Review)","_key":"106aa68fae7b0","_type":"span","marks":[]}]},{"style":"normal","_key":"52941e346457","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"7a0401676a630"}],"_type":"block"}],"_updatedAt":"2023-07-24T15:24:37Z"},{"seoNoIndex":false,"slug":{"current":"/news/we-are-pleased-to-announce-that-david-heal's-faculty-pos","_type":"slug"},"_type":"article","_id":"4cd89593-f951-4067-917c-14229a1c753d","richText":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Part of the mission of DevelRx is to support academic science in the UK. Since the inauguration of DevelRx in 2020, we have collaborated with the University of Bath by supporting PhD programmes and undergraduate and post-graduate teaching. We are pleased to announce that the partnership between DevelRx and Bath University has been consolidated by extending David Heal’s faculty position as Visiting Professor in the Department of Life Sciences until 2026.","_key":"1dc1c85bfdda0"}],"_type":"block","style":"normal","_key":"3f78a0e4af50"}],"_updatedAt":"2023-07-07T11:27:59Z","description":"Part of the mission of DevelRx is to support academic science in the UK. Since the inauguration of DevelRx in 2020, we have collaborated with the University of Bath by supporting PhD programmes and undergraduate and post-graduate teaching. ","categories":null,"image":{"alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"},"_type":"image"},"seoEnabled":true,"title":"We are pleased to announce that David Heal’s faculty position as Visiting Professor at the University of Bath has been extended","date":"2023-07-07","_rev":"LJLVh4Cn36FUR6uxaBbFQR","_createdAt":"2023-07-07T11:12:57Z"},{"slug":{"current":"/news/congratulations-to-our-phd-student-eloise-kuijer-who-wil","_type":"slug"},"description":"Congratulations to Eloise Kuijer, our PhD student with Dr Chris Bailey, Professor Sue Wonnacott and Dr Sarah Bailey, Department of Life Sciences, University of Bath, who has been invited to take part in a symposium sponsored by the British Pharmacological Society on ‘GPCRs in addiction’ on 5th July 2023 at the 19th World Congress of Basic and Clinical Pharmacology to be held at the Scottish Event Campus in Glasgow. ","seoEnabled":true,"richText":[{"_type":"block","style":"normal","_key":"1394dc9b3df5","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Congratulations to Eloise Kuijer, our PhD student with Dr Chris Bailey, Professor Sue Wonnacott and Dr Sarah Bailey, Department of Life Sciences, University of Bath, who has been invited to take part in a symposium sponsored by the British Pharmacological Society on ‘GPCRs in addiction’ on 5th July 2023 at the 19th World Congress of Basic and Clinical Pharmacology to be held at the Scottish Event Campus in Glasgow. If you are at WCP2023 do go along and listen to her talk on electrophysiological analysis of kappa opioid receptor activation in mouse paraventricular thalamus.","_key":"715414adca600"}]}],"_createdAt":"2023-06-23T14:58:16Z","_rev":"0HUDzV2xN6w5wtAawRtcXg","_type":"article","_id":"4787b54e-231b-4d6b-ab72-97ab28bfcc41","title":"Congratulations to our PhD student, Eloise Kuijer, who will be speaking at WCP2023, Glasgow, July 2023","date":"2023-06-22","image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"categories":null,"seoNoIndex":false,"_updatedAt":"2023-06-23T15:36:27Z"},{"_id":"37e9742b-e328-4d67-a980-3ad8c266326b","_updatedAt":"2023-05-08T13:28:02Z","_type":"article","richText":[{"_key":"6dd211752e80","markDefs":[],"children":[{"_key":"9bd5683a47470","_type":"span","marks":[],"text":"DevelRx will be participating in the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence to be held at the Sheraton Denver Downtown Hotel, Denver, Colorado, USA, 17th-21st June, 2023. "}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"If you are developing novel centrally-acting compounds and would like to learn more about our services come along and meet us at one of our posters.","_key":"7eb904a39965"}],"_type":"block","style":"normal","_key":"2b0e64b1d1c5"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"f8d10d15a50f0"}],"_type":"block","style":"normal","_key":"ba681ca869f1"},{"markDefs":[],"children":[{"marks":["strong"],"text":"M164. Experimental Approaches to Screen for Efficacy of Novel Psychedelics. ","_key":"add36073f7460","_type":"span"},{"_key":"7976bf1849c60","_type":"span","marks":[],"text":"Sharon Smith, Jane Gosden & David Heal. Monday 19th June 2023. 5 pm-6.30 pm. Plaza Exhibit"}],"_type":"block","style":"normal","_key":"ae3c95325449"},{"markDefs":[],"children":[{"_key":"3cfa353d33db0","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"cd20f2ba6758"},{"style":"normal","_key":"c0dbca7b6765","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"M169. Valid and Invalid Designs for Conducting Drug Discrimination Experiments in Abuse Potential Evaluations. ","_key":"9acc0e47ea550"},{"_type":"span","marks":[],"text":"David Heal, Jane Gosden & Sharon Smith. Monday 19th June 2023. 5 pm-6.30 pm. Plaza Exhibit","_key":"9acc0e47ea551"}],"_type":"block"},{"markDefs":[],"children":[{"_key":"946739cd50070","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"e8ea01637743"},{"markDefs":[],"children":[{"marks":["strong"],"text":"T161. Essential Experimental Screening to Evaluate the Safety of Novel Psychedelics. ","_key":"cba087888d090","_type":"span"},{"marks":[],"text":"Jane Gosden, Sharon Smith, Christopher Atterwill & David Heal. Tuesday 20th June 2023. 5.15 pm-6.45 pm. Plaza Exhibit","_key":"520fa57bee3c0","_type":"span"}],"_type":"block","style":"normal","_key":"5cea4bdc445f"},{"markDefs":[],"children":[{"_key":"3f4b9bdae8f1","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"d64dc9ba2986"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"We also have a poster in collaboration with Neumora Therapeutics","_key":"38935eef0929"}],"_type":"block","style":"normal","_key":"5d237f7e5b8e"},{"markDefs":[],"children":[{"_key":"9708af82bd84","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"07c726d3f390"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"S102. NMRA-140, a Novel and Selective Kappa Opioid Receptor Antagonist: Mode of Action Profiling Studies Demonstrate No Opioid Agonist Properties Implicated in Opioid-Related Abuse. ","_key":"17543e8f419c0"},{"text":"Filomene Morrison, Lori Jean Van Orden, Karla Zeitz,David Heal, Sharon Smith & Tanya L. Wallace.  Sunday 18th June 2023. 5.15-6.45 pm. Plaza Exhibit.","_key":"efdeead73c520","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"55ca1b8744d4"}],"seoEnabled":true,"_rev":"vuzvVDrYQXJOMHanVG8v8e","_createdAt":"2023-04-13T14:33:52Z","image":{"alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"},"_type":"image"},"date":"2023-05-08","seoNoIndex":false,"slug":{"current":"/news/meet-us-at-the-cpdd-85th-annual-scientific-meeting-denve","_type":"slug"},"title":"Meet us at the CPDD 85th Annual Scientific Meeting, Denver, CO, 17th-21st June 2023","description":"DevelRx will be participating in the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence to be held at the Sheraton Denver Downtown Hotel, Denver, Colorado, USA, 17th-21st June, 2023. If you are developing novel centrally-acting compounds and would like to learn more about our services come along and meet us at one of our posters.","categories":null},{"categories":null,"description":"We have recently had our first book chapter published in Mandarin Chinese. The article on abuse and dependence testing procedures is in a book on safety pharmacology that was written to support drug safety evaluations in China and other Asian countries.","_createdAt":"2023-05-08T13:27:07Z","seoEnabled":true,"image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"_rev":"CKoJmXlM50fHJKgxSCoYIX","title":"Chapter in Mandarin Chinese in book on safety pharmacology ","_updatedAt":"2023-05-09T08:13:22Z","richText":[{"style":"normal","_key":"561aaf95dcdf","markDefs":[],"children":[{"_type":"span","marks":[],"text":"We have recently had our first book chapter published in Mandarin Chinese. ","_key":"9bd2af89c6a00"}],"_type":"block"},{"markDefs":[],"children":[{"text":"‘A Guide to the Evaluation of the Abuse and Dependence Potential of Novel CNS-active Drug-candidates’ David J Heal, Jane Gosden, Sharon L Smith. In: Introduction of Safety Pharmacology. Editor-in-Chief: Jufeng Wang (former Director of the National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, China Food and Drug Administration (CFDA), Beijing, China), Sun Yat-sen University Press, 2022. ","_key":"4df95d5d1726","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"4fc145388fe6"},{"_key":"b389a3a4c1ec","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The book was written to assist the Chinese Safety Pharmacology Society and is intended to support drug safety evaluations in China and other Asian countries. ","_key":"14b1bfbac828"}],"_type":"block","style":"normal"},{"_key":"7c2f88eb35de","markDefs":[],"children":[{"marks":[],"text":"Please contact us for further information about this article.","_key":"28a7e72cd3ad","_type":"span"}],"_type":"block","style":"normal"}],"_type":"article","slug":{"current":"/news/chapter-in-mandarin-chinese-in-book-on-safety-pharmacology","_type":"slug"},"seoNoIndex":false,"_id":"1f264f1f-0221-442e-a9e0-f22e726d7cb8","date":"2023-05-07"},{"seoNoIndex":false,"_updatedAt":"2023-05-08T13:15:31Z","description":"This paper outlines strategies for the non-clinical and clinical evaluation of the abuse potential of psychedelics, ie serotonergic hallucinogens and entactogens for new drug applications to the FDA and scheduling recommendations. ","slug":{"current":"/news/psychedelic-drug-abuse-potential-assessment-for-new-drug","_type":"slug"},"seoEnabled":true,"image":{"asset":{"_type":"reference","_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png"},"_type":"image","alt":"DevelRx logo"},"categories":null,"_id":"f40461ab-a6ce-4dad-8590-caf129876655","_rev":"CKoJmXlM50fHJKgxSBpQI8","_type":"article","date":"2023-04-11","richText":[{"_type":"block","style":"normal","_key":"320986d61d08","markDefs":[{"customLink":{"external":"https://www.pinneyassociates.com/","blank":true,"_type":"customUrl"},"_type":"customLink","_key":"163c0f05f9ea"}],"children":[{"_type":"span","marks":[],"text":"We are pleased to announce publication of this article by the Journal of Psychopharmacology. The paper outlines strategies for the non-clinical and clinical evaluation of the abuse potential of psychedelics, ie serotonergic hallucinogens such as psilocybin and entactogens such as MDMA for new drug applications to the FDA and scheduling recommendations. It was co-authored by David Heal and Sharon Smith of DevelRx in collaboration with Jack Henningfield and Judy Ashworth of ","_key":"e079eeabbada0"},{"_type":"span","marks":["163c0f05f9ea"],"text":"Pinney Associates","_key":"d71960ec3411"},{"_type":"span","marks":[],"text":".","_key":"605cacdd74e1"}]},{"markDefs":[{"_key":"7bd73cd9655e","customLink":{"_type":"customUrl","external":"https://journals.sagepub.com/doi/10.1177/02698811221140004","blank":true},"_type":"customLink"}],"children":[{"_type":"span","marks":[],"text":"Further details of the publication are given ","_key":"b598f01bf20f0"},{"text":"here","_key":"21a038d2f3de","_type":"span","marks":["7bd73cd9655e"]},{"_type":"span","marks":[],"text":".","_key":"4eb6598ce92c"}],"_type":"block","style":"normal","_key":"dbf95d3eb3c1"},{"children":[{"text":"Please ","_key":"2d16fa03b7760","_type":"span","marks":[]},{"_type":"span","marks":["d0d1cd4869e3"],"text":"get in touch","_key":"f1be4b6840ae"},{"text":" if you would like to discuss our services for evaluating the abuse potential of psychedelic drugs. These include 8-factor analyses for new drug applications.","_key":"5b953a56202a","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"5b34d92105cb","markDefs":[{"_type":"customLink","_key":"d0d1cd4869e3","customLink":{"external":"https://develrx.com/contact","blank":true,"_type":"customUrl"}}]}],"title":"Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective ","_createdAt":"2023-02-01T11:55:40Z"},{"description":"We are pleased to announce that our application for a 50 : 50 DevelRx : University Research Studentship Award (URSA) funded PhD studentship with the University of Bath has been accepted.","categories":null,"_type":"article","slug":{"current":"/news/we-are-pleased-to-announce-new-joint-develrx-:-ursa-fund","_type":"slug"},"image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"seoEnabled":true,"_createdAt":"2023-05-09T08:08:48Z","_rev":"vuzvVDrYQXJOMHanVHV4Wt","title":"We are pleased to announce new joint DevelRx : URSA-funded PhD studentship with the University of Bath ","richText":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"We are pleased to announce that our application for a 50 : 50 DevelRx : University Research Studentship Award (URSA) funded PhD studentship with the University of Bath has been accepted. The project will be supervised between Dr Chris Bailey and Dr Sarah Bailey in the Department of Life Sciences and DevelRx. We are very much looking forward to the project which will start in October 2023 and will research the role of opioid receptors in the paraventricular thalamus in motivational memory initiating drug-seeking behaviour.","_key":"10b06e575c330"}],"_type":"block","style":"normal","_key":"bf91fa1c6e7f"}],"date":"2023-04-10","_id":"a845374e-3795-4b0f-969b-0796dacaf39b","seoNoIndex":false,"_updatedAt":"2023-05-09T08:31:51Z"},{"_rev":"0h9STrNxKNisYLESHB3nDg","_createdAt":"2023-04-13T14:24:09Z","date":"2023-04-10","_type":"article","title":"Novel kappa opioid antagonist lacks opioid agonist properties implicated in opioid-related abuse","description":"If you are developing opioid antagonists for therapeutic use, it is important to use non-clinical studies to profile the effects of the compounds at mu, kappa and delta opioid receptors to confirm mode of action and evaluate the potential for adverse side effects associated with agonist activity at opioid receptors. ","_updatedAt":"2023-04-14T10:56:19Z","seoNoIndex":false,"categories":null,"image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"_id":"e2fe4ddd-6c81-46ec-b429-11f81a99a3e2","slug":{"current":"/news/novel-kappa-opioid-antagonist-lacks-opioid-agonist-prope","_type":"slug"},"richText":[{"_type":"block","style":"normal","_key":"c4a419d6a1b3","markDefs":[],"children":[{"_type":"span","marks":[],"text":"If you are developing opioid antagonists for therapeutic use, it is important to use non-clinical studies to profile the effects of the compounds at mu, kappa and delta opioid receptors to confirm mode of action and evaluate the potential for adverse side effects associated with agonist activity at opioid receptors. ","_key":"d54928cecf8f0"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"NMRA-140 is a selective kappa opioid receptor antagonist being developed for the treatment of depression by Neumora Therapeutics. ","_key":"c71caf8430fe"}],"_type":"block","style":"normal","_key":"12b6ed828686"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Filomene Morrison of Neumora Therapeutics will be presenting the following poster at the Annual Meeting of the Society of Biological Psychiatry to be held at the Hilton San Diego Bayfront, San Diego, California, 27th-29th April, 2023. ","_key":"804c72fe4bfb"}],"_type":"block","style":"normal","_key":"6e9d0deed256"},{"style":"normal","_key":"7bbe764f99b9","markDefs":[],"children":[{"marks":[],"text":"'NMRA-140, a Novel and Selective Kappa Opioid Receptor Antagonist: Mode of Action Profiling Studies Demonstrate No Opioid Agonist Properties Implicated in Opioid-Related Abuse' Filomene Morrison, Lori Jean Van Orden, Karla Zeitz, David Heal, Sharon Smith, Tanya L. Wallace","_key":"958aaeabdec40","_type":"span"}],"_type":"block"},{"_type":"block","style":"normal","_key":"d7590a310b70","markDefs":[],"children":[{"_key":"e7c35c04aa06","_type":"span","marks":[],"text":"This poster was produced in collaboration with two of our consultants (David Heal and Sharon Smith)."}]}],"seoEnabled":true},{"_rev":"0h9STrNxKNisYLESH5Lb1U","richText":[{"children":[{"_type":"span","marks":[],"text":"Eloise Kuijer, our PhD student with Dr Chris Bailey, Professor Sue Wonnacott and Dr Sarah Bailey, Department of Life Sciences, University of Bath, will be presenting the results of her research into the electrophysiological and behavioural effects of activation of kappa opioid receptors at KappaCon 2023, the 7th Conference on the ‘Therapeutic Potential of Kappa Opioids in Pain and Addiction’ to be held 29th to 31st March 2023 at the National Institutes of Health (NIH) Campus, Bethesda, Maryland, USA.","_key":"a7df791fc345"}],"_type":"block","style":"normal","_key":"7fe6452f63ff","markDefs":[]},{"style":"normal","_key":"9ce5c5f35cd8","markDefs":[],"children":[{"marks":[],"text":"If you are at the meeting please pop along to see her Hot Topic talk or meet her at one of her posters.","_key":"efab34eca8a30","_type":"span"}],"_type":"block"},{"style":"normal","_key":"a1f50e871b30","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Hot topic oral communication, Friday 31st March 3:50 PM\nEJ Kuijer, SJ Bailey, DJ Heal, S Smith, S Wonnacott, & CP Bailey ","_key":"eb50cc68fb3d0"},{"_type":"span","marks":["strong"],"text":"Electrophysiological analysis of kappa opioid receptor activation in mouse paraventricular thalamus","_key":"d4144ae894e0"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Poster 10. EJ Kuijer, SJ Bailey, DJ Heal, S Smith, S Wonnacott, CP Bailey ","_key":"4a070c01a0c70"},{"_type":"span","marks":["strong"],"text":"Nalfurafine is aversive in doses that produce equi-effective antinociception to U50,488","_key":"d79bd7cc9332"}],"_type":"block","style":"normal","_key":"21702d751c51"},{"_type":"block","style":"normal","_key":"c39d04f2e972","markDefs":[],"children":[{"_key":"02e0c6062aa00","_type":"span","marks":[],"text":"Poster 11. EJ Kuijer, SJ Bailey, DJ Heal, S Smith, S Wonnacott, CP Bailey "},{"marks":["strong"],"text":"A single injection of kappa opioid receptor agonist inhibits contextual heroin cues by counter-conditioning, not by enhancing extinction","_key":"c9cc4a5d3088","_type":"span"}]}],"_updatedAt":"2023-04-13T14:41:16Z","image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"_type":"article","_id":"65bb1281-274c-4bc4-84c1-d862cb32c58f","date":"2023-01-31","seoEnabled":true,"seoNoIndex":false,"title":"New research on kappa opioid receptor activation to be presented at KappaCon 2023","slug":{"current":"/news/new-research-on-kappa-opioid-receptor-activation-to-be-p","_type":"slug"},"description":"Eloise Kuijer, our PhD student with the University of Bath, will be presenting the results of her research into the effects of activating kappa opioid receptors at KappaCon 2023","_createdAt":"2023-03-22T11:59:01Z","categories":null},{"_createdAt":"2023-01-16T13:21:13Z","_rev":"drDVwmdZ7WTxDAuOR0C6IU","_type":"article","richText":[{"markDefs":[],"children":[{"text":"Our latest paper 'Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines' is now available online as part of the Special Issue of Neuropharmacology (National Institutes of Health Psilocybin Research Speaker Series) edited by David Heal, Jack Henningfield, Sharon Smith and Sean Belouin. ","_key":"6c296f778e1c0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"1bf9fd874173"},{"_key":"5daddbd609d4","markDefs":[{"_type":"customLink","_key":"ac03014c5bd1","customLink":{"external":"https://www.sciencedirect.com/journal/neuropharmacology/special-issue/10TFVWPHZCS","blank":true,"_type":"customUrl"}},{"_type":"customLink","_key":"4e02a6392dde","customLink":{"blank":true,"_type":"customUrl","external":"https://cdn.sanity.io/files/9f1xpw6w/production/e5c8496b0193135dc3fbf754da9091a70c44c767.pdf"}}],"children":[{"_type":"span","marks":[],"text":"You can read the paper ","_key":"68a2809cbe6f"},{"_type":"span","marks":["4e02a6392dde"],"text":"here","_key":"3abc3072dac2"},{"_type":"span","marks":[],"text":" and find out more about the Special Issue of Neuropharmacology ","_key":"ba004559b8ac"},{"_type":"span","marks":["ac03014c5bd1"],"text":"here","_key":"24d32f35fe31"}],"_type":"block","style":"normal"}],"date":"2023-01-16","description":"Our latest paper describing screening strategies for drug discovery and development to deliver more effective and safer psychedelics and entactogens for clinical use is now available online ","seoEnabled":true,"_updatedAt":"2023-01-16T13:54:17Z","slug":{"current":"/news/experimental-strategies-to-discover-and-develop-the-next","_type":"slug"},"_id":"3ffd1944-04f5-4204-ba85-fed935fa038a","seoNoIndex":false,"image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"categories":null,"title":"Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines"},{"richText":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Congratulations to one of our Directors, Professor David Heal, who in 2022 was elected an Honorary Fellow of the British Pharmacological Society. Honorary Fellowships, the highest award of the BPS, are elected for life in recognition of sustained excellence and leadership in science, healthcare, and public service. David received the award for his outstanding contributions to research, including drug discovery and development.","_key":"3f5bb6e876e40"}],"_type":"block","style":"normal","_key":"133bce546aa7"}],"_createdAt":"2023-01-16T12:11:14Z","seoNoIndex":false,"_rev":"GqO0wImCyXdqLGKWk2Ll6p","_type":"article","description":"Congratulations to David Heal on being elected an Honorary Fellow of the British Pharmacological Society for sustained excellence in research, including drug discovery and development","title":"Congratulations to David Heal on being elected an Honorary Fellow of the BPS","seoEnabled":true,"slug":{"current":"/news/congratulations-to-david-heal-on-being-elected","_type":"slug"},"_updatedAt":"2023-01-16T13:19:17Z","categories":null,"_id":"7dc1e1d5-2cb7-48c7-bcf6-a96f5d15bdb1","date":"2023-01-15","image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}}},{"_type":"article","description":"David Heal will be attending the 61st Annual Meeting of the ACNP (American College of Neuropsychopharmacology), 4th to 7th December 2022, JW Marriott Desert Ridge Resort and Spa, Phoenix, Arizona. If you would like to see David at the ACNP to discuss our consultancy services in the areas of drug abuse evaluation and CNS and metabolic disorders please contact inform@develrx.com.","seoEnabled":true,"slug":{"current":"/news/meet-david-heal-at-the-acnp-meeting-in-phoenix-december-","_type":"slug"},"categories":null,"_id":"cfaf873f-46fa-492b-a4db-e777d36589e7","date":"2022-11-14","_rev":"dJY9TrOOTWOOFACA43oVFU","title":"Meet David Heal at the ACNP meeting in Phoenix, December 2022","richText":[{"_key":"7eb97d1fc8fd","markDefs":[{"_key":"15535a48e9d7","customLink":{"external":"mailto:inform@develrx.com","blank":false,"_type":"customUrl"},"_type":"customLink"}],"children":[{"text":"David Heal will be attending the 61st Annual Meeting of the ACNP (American College of Neuropsychopharmacology), 4th to 7th December 2022, JW Marriott Desert Ridge Resort and Spa, Phoenix, Arizona. If you would like to see David at the ACNP to discuss our consultancy services in the areas of drug abuse evaluation and CNS and metabolic disorders please contact ","_key":"ee0a4efc60b80","_type":"span","marks":[]},{"_key":"a4b403333192","_type":"span","marks":["15535a48e9d7"],"text":"inform@develrx.com"},{"_type":"span","marks":[],"text":".","_key":"35b7208ad1b6"}],"_type":"block","style":"normal"}],"image":{"_type":"image","alt":"DevelRx logo","asset":{"_ref":"image-61994bbde1bce0dcb0a9845efc504acffa280bd3-1200x630-png","_type":"reference"}},"_createdAt":"2022-11-14T15:46:50Z","_updatedAt":"2023-01-16T12:28:22Z","seoNoIndex":false},{"richText":[{"style":"normal","_key":"59575b5dbc89","markDefs":[],"children":[{"_key":"37ad38841f460","_type":"span","marks":[],"text":"One of our Directors, David Heal, was co-author of this new article 'Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling' which is now available online as part of a Special Issue of Neuropharmacology (National Institutes of Health Psilocybin Research Speaker Series) edited by David Heal, Jack Henningfield, Sharon Smith and Sean Belouin."}],"_type":"block"},{"markDefs":[{"_type":"customLink","_key":"48a2b40efd2c","customLink":{"external":"https://www.sciencedirect.com/journal/neuropharmacology/special-issue/10TFVWPHZCS","blank":true,"_type":"customUrl"}},{"_type":"customLink","_key":"27d5f0f2d597","customLink":{"_type":"customUrl","external":"https://cdn.sanity.io/files/9f1xpw6w/production/28ba379edf00925430a327c9dbf164708133c584.pdf","blank":true}}],"children":[{"_type":"span","marks":[],"text":"You can read the paper ","_key":"5adb01e363b80"},{"_type":"span","marks":["27d5f0f2d597"],"text":"here","_key":"1e939eef01d3"},{"_type":"span","marks":[],"text":" and find out more about the Special Issue of Neuropharmacology ","_key":"3ab89d0a2248"},{"_type":"span","marks":["48a2b40efd2c"],"text":"here","_key":"52e6e6c01bc1"}],"_type":"block","style":"normal","_key":"84c3c95af7e1"}],"title":"David Heal contributes to new article 'Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling' ","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_type":"article","_id":"d9168100-3092-4a1f-9ed3-1da20c7d75b0","seoEnabled":true,"_updatedAt":"2023-01-16T13:38:47Z","date":"2022-08-29","categories":null,"_createdAt":"2022-09-12T15:59:10Z","_rev":"GqO0wImCyXdqLGKWk2PfSZ","slug":{"current":"/news/david-heal-contributes-to-new-article-'psychedelic-drug-","_type":"slug"},"seoNoIndex":false},{"richText":[{"_type":"block","style":"normal","_key":"d124985509c4","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Do you have a pipeline of cannabinoid product candidates? If so, don’t miss this important paper on the preclinical evaluation of the abuse potential of cannabidiol (CBD).","_key":"40dba9db1b590"}]},{"_key":"37116a781b2c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Two of our experts, David Heal and Sharon Smith, are co-authors of this key publication and we are delighted that it was hand-picked by Susan Wood as the Journal of Pharmacology and Experimental Therapeutics Editor's Choice in July 2022.","_key":"e9c5ce76fe890"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The paper describes the results of self-administration, drug discrimination and physical dependence studies in animals used to support the approval of an oral formulation of CBD (Epidiolex in the US; Epidyolex in Europe), for treating seizures associated with rare and severe forms of epilepsy. CBD did not produce reliable self-administration. It did not increase drug-lever responding in rats trained to discriminate midazolam. Furthermore, CBD did not produce withdrawal signs on discontinuation of chronic treatment.","_key":"4abd67c719120"}],"_type":"block","style":"normal","_key":"377617d914c0"},{"children":[{"_type":"span","marks":[],"text":"Demonstrating that CBD was not rewarding and did not produce physical dependence was a prerequisite to ensuring the drug was not scheduled as a Controlled Drug, thus maximizing its availability to prescribers and patients.","_key":"c99462b722980"}],"_type":"block","style":"normal","_key":"b864ec9122ac","markDefs":[]},{"_key":"9a9eb9f4fb0f","markDefs":[],"children":[{"text":"The full details of the publication are:","_key":"778a5336ef410","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Gray RA, Heal DJ, Maguire DR, Gerak LR, Javors MA, Smith S, France CP. Preclinical assessment of the abuse potential of purified botanical cannabidiol: self-administration, drug discrimination, and physical dependence. J Pharmacol Exp Ther, 2022 Jul; 382(1): 54-65. doi: 10.1124/jpet.121.000988. Epub 2022 Apr 30.","_key":"2a2e6b040bb40"}],"_type":"block","style":"normal","_key":"4230230b4634"},{"_key":"3e6c3f4ed25a","markDefs":[{"_type":"customLink","_key":"36906134c0b8","customLink":{"external":"https://pubmed.ncbi.nlm.nih.gov/35489780/","blank":true,"_type":"customUrl"}},{"_type":"customLink","_key":"3e1a1f342058","customLink":{"external":"/contact","_type":"customUrl"}}],"children":[{"text":"You can find out more by clicking ","_key":"7c2e73c84f260","_type":"span","marks":[]},{"_key":"9c3c57780915","_type":"span","marks":["36906134c0b8"],"text":"here"},{"_type":"span","marks":[],"text":" or by ","_key":"c7c38b0ef15f"},{"text":"contacting us","_key":"9eb2d58d4d72","_type":"span","marks":["3e1a1f342058"]},{"_type":"span","marks":[],"text":".","_key":"6ff87d7d1880"}],"_type":"block","style":"normal"}],"seoEnabled":true,"_updatedAt":"2022-10-20T10:27:57Z","_createdAt":"2022-09-12T15:58:32Z","_rev":"feQG1v5Q2NahcmQBPTuomp","categories":null,"seoNoIndex":false,"title":"We are pleased to announce that 'Preclinical evaluation of the abuse potential of purified botanical cannabidiol' was the JPET Editor's Choice in July 2022 ","_type":"article","slug":{"current":"/news/we-are-pleased-to-announce-that-'preclinical-evaluation-","_type":"slug"},"date":"2022-08-04","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_id":"09fc1a3c-5ae1-4143-844d-5968a0fb53c1"},{"date":"2022-08-01","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"seoNoIndex":false,"title":"Congratulations to Eloise Kuijer, our PhD student with the University of Bath, for presentation of a poster at INRC 2022","_updatedAt":"2022-10-20T10:36:37Z","slug":{"_type":"slug","current":"/news/congratulations-to-eloise-kuijer-our-phd-student-with-th"},"categories":null,"_rev":"8FY4bwtHg6TsUVnHx91J9C","seoEnabled":true,"_createdAt":"2022-09-12T15:53:01Z","_type":"article","_id":"3fc890fc-4dce-4191-ba1f-615c175e834f","richText":[{"markDefs":[],"children":[{"text":"Congratulations to Eloise Kuijer, our PhD student with Dr Chris Bailey, Professor Sue Wonnacott and Dr Sarah Bailey, University of Bath, for presenting a poster on the results of her research at the International Narcotics Research Conference in Valencia, Spain, 4th to 8th July, 2022.","_key":"4830928b33e50","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"14d14c3dfd63"},{"children":[{"marks":[],"text":"Kuijer E, Heal D, Bailey S, Smith S, Wonnacott S, Bailey C. Kappa opioid receptor currents in mouse paraventricular thalamus. Poster Session 1. Poster No 76.","_key":"d8d3423f6e320","_type":"span"}],"_type":"block","style":"normal","_key":"3f9973bf55d5","markDefs":[]},{"children":[{"marks":[],"text":"You can see the poster by clicking ","_key":"59bb61c9500e0","_type":"span"},{"marks":["6f4555f21dfb"],"text":"here","_key":"ade0e72e1ed8","_type":"span"}],"_type":"block","style":"normal","_key":"66b93dc43765","markDefs":[{"_type":"customLink","_key":"6f4555f21dfb","customLink":{"external":"https://cdn.sanity.io/files/9f1xpw6w/production/606c8f006c7dbeb509cb0cd2a716c15d3c187e41.pdf","blank":true,"_type":"customUrl"}}]}]},{"seoNoIndex":false,"_id":"55bc7b15-aa35-44cf-b7a9-0e9c6022c2a6","categories":null,"_createdAt":"2022-09-12T15:50:00Z","seoEnabled":true,"slug":{"current":"/news/develrx-announces-publication-of-book-chapter-'new-drugs","_type":"slug"},"image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_updatedAt":"2022-10-20T09:50:46Z","_rev":"Rejt3t5Fpi8uEcdG3YJGPW","_type":"article","date":"2022-07-30","richText":[{"children":[{"_key":"ce8008e4a4d90","_type":"span","marks":[],"text":"We are pleased to announce the publication of our book chapter ‘New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development’ in ‘New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder’ Stanford SC, Scriberras E (Eds). Current Topics in Behavioral Neurosciences, 2022; 57: 79-126. Springer."}],"_type":"block","style":"normal","_key":"734848ea3180","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"In the chapter we review the current status of drugs to treat ADHD, the clinical and non-clinical pharmacology of approved drugs to treat the disorder and the advances in R&D in the search for new drugs to treat ADHD. Our overview confirms the hypothesis that clinically effective ADHD drugs indirectly or directly increase catecholaminergic neurotransmission in the prefrontal cortex. New drugs approved for ADHD are catecholaminergic reuptake inhibitors and releasing agents or selective noradrenaline reuptake inhibitors. The focus continues to be on developing catecholaminergic and noradrenergic drugs and there is a dearth of drug-candidates with novel mechanisms entering development. However, considerable progress in ADHD pharmacotherapy has been achieved by once-daily medications with an extended duration of action and prodrugs which improve compliance, deliver greater efficacy and reduce risks for diversion and abuse.","_key":"d6719f3a61440"}],"_type":"block","style":"normal","_key":"6f0465e3ce80"},{"_key":"247ba677f95d","markDefs":[{"_type":"customLink","_key":"6bc1a3b93533","customLink":{"_type":"customUrl","external":"https://cdn.sanity.io/files/9f1xpw6w/production/848de3b9c9c391bb425aac7b009275c845fda448.pdf"}}],"children":[{"marks":[],"text":"You can read our book chapter ","_key":"ba14e99a05cc0","_type":"span"},{"_type":"span","marks":["6bc1a3b93533"],"text":"here","_key":"44ce9cc07e96"}],"_type":"block","style":"normal"},{"_key":"ca0e10afcc8b","markDefs":[{"_type":"customLink","_key":"d0620896b059","customLink":{"external":"https://link.springer.com/book/10.1007/978-3-031-11802-9","blank":true,"_type":"customUrl"}}],"children":[{"marks":[],"text":"You can find further information about the book 'New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder' ","_key":"825082f7ec890","_type":"span"},{"_type":"span","marks":["d0620896b059"],"text":"here","_key":"b8739fbe7af1"}],"_type":"block","style":"normal"}],"title":"DevelRx announces publication of book chapter 'New Drugs to treat ADHD: Opportunities and Challenges in Research and Development' "},{"seoNoIndex":false,"_createdAt":"2022-09-12T15:48:51Z","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_rev":"8FY4bwtHg6TsUVnHx8z1Ba","richText":[{"_type":"block","style":"normal","_key":"ab052c20778b","markDefs":[{"customLink":{"external":"https://sintalica.com/about","blank":true,"_type":"customUrl"},"_type":"customLink","_key":"433c7268b7e3"},{"_type":"customLink","_key":"6aebc81f8d04","customLink":{"external":"https://www.pinneyassociates.com/","blank":true,"_type":"customUrl"}}],"children":[{"_type":"span","marks":[],"text":"We are pleased to announce that one of our Directors, David Heal, along with Judy Ashworth, VP of Rx Strategic Services and CMO, Pinney Associates Inc, have been appointed as Scientific Advisors to ","_key":"37e042b073d10"},{"marks":["433c7268b7e3"],"text":"Sintalica Bioscience","_key":"0d54b47bfcff","_type":"span"},{"marks":[],"text":", a company developing novel psychedelic treatments for chronic pain. This marks another successful collaboration where the complementary skills of DevelRx and ","_key":"063ad30635c9","_type":"span"},{"_type":"span","marks":["6aebc81f8d04"],"text":"Pinney Associates","_key":"708c77ca01f1"},{"_type":"span","marks":[],"text":", in the non-clinical and clinical development of CNS-active drugs, can be used to benefit our clients.","_key":"9db572f56212"}]},{"_type":"block","style":"normal","_key":"f22a4b189e75","markDefs":[{"_type":"customLink","_key":"f8dc36fb9ffb","customLink":{"external":"/contact","_type":"customUrl"}}],"children":[{"_type":"span","marks":[],"text":"Please ","_key":"7caa01e3a1a50"},{"_type":"span","marks":["f8dc36fb9ffb"],"text":"contact us","_key":"0274257385ab"},{"_type":"span","marks":[],"text":" for further information about our experience and expertise in the area of psychedelic drug development.","_key":"5acaef66d39e"}]}],"date":"2022-07-22","categories":null,"_type":"article","title":"David Heal becomes Scientific Advisor for company developing novel psychedelics","_updatedAt":"2022-10-20T10:18:46Z","seoEnabled":true,"slug":{"current":"/news/david-heal-becomes-scientific-advisor-for-company-develo","_type":"slug"},"_id":"e46668e1-f09b-4d9f-99aa-6ab02231e22d"},{"_createdAt":"2022-09-12T15:46:18Z","_rev":"Rejt3t5Fpi8uEcdG3YM3Si","_type":"article","seoNoIndex":false,"categories":null,"title":"DevelRx to participate in Workshop 'Key considerations in planning, interpreting and reporting animal model studies relevant to psychiatric illness' Join us at the BAP Summer Meeting, London, UK, 24th July 2022","_updatedAt":"2022-10-20T10:14:57Z","slug":{"current":"/news/develrx-to-participate-in-workshop-'key-considerations-i","_type":"slug"},"date":"2022-06-26","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_id":"8290f834-abc6-4406-900a-3079fa1d37c1","richText":[{"_type":"block","style":"normal","_key":"acc5e5f69e9a","markDefs":[{"_type":"customLink","_key":"fc4eeed4c7e1","customLink":{"external":"https://www.bap.org.uk/summermeeting","blank":true,"_type":"customUrl"}},{"_type":"customLink","_key":"d74265217c82","customLink":{"external":"/contact","_type":"customUrl"}}],"children":[{"_type":"span","marks":[],"text":"We are pleased to announce that David Heal has been invited to participate in an interactive workshop ‘Key considerations in planning, interpreting and reporting animal model studies relevant to psychiatric illness’ which forms part of the Summer Meeting of the British Association for Psychopharmacology, to be held on the South Kensington Campus of Imperial College, London, UK on 24th July, 2022. Further details of the BAP meeting can be found ","_key":"4951909620bc0"},{"_type":"span","marks":["fc4eeed4c7e1"],"text":"here","_key":"05e5907f229d"},{"_type":"span","marks":[],"text":". Please ","_key":"a8a99840867b"},{"_key":"01aebc126d27","_type":"span","marks":["d74265217c82"],"text":"contact us"},{"text":" to schedule a meeting with David at the BAP.","_key":"b4a20b6f89f5","_type":"span","marks":[]}]}],"seoEnabled":true},{"_type":"article","richText":[{"children":[{"text":"Interested in developing better drugs to treat mental illness? David Heal has recently joined a preclinical sub-panel of the editorial board of the Journal of Psychopharmacology. The group have been debating the challenges of translational psychopharmacology. Advances in our understanding of the neurobiology of neuropsychiatric conditions and development of more clinically relevant read-outs by collaboration between clinical and preclinical scientists should improve the alignment of human subjective experiences with animal behaviour and lead to better preclinical models for CNS drug discovery. You can read the full British Association for Psychopharmacology editorial ‘Improving the validity and translation of preclinical research’ which was published in J Psychopharmacol. June 2022 ","_key":"ec7ecc2a06100","_type":"span","marks":[]},{"_type":"span","marks":["d3cf35f69bee"],"text":"here","_key":"82219fc64f15"},{"_type":"span","marks":[],"text":".","_key":"dc123f0f1f1b"}],"_type":"block","style":"normal","_key":"47456119ffec","markDefs":[{"_type":"customLink","_key":"d3cf35f69bee","customLink":{"external":"https://journals.sagepub.com/doi/full/10.1177/02698811221104064","blank":true,"_type":"customUrl"}}]}],"seoEnabled":true,"_createdAt":"2022-09-12T15:44:23Z","_id":"e53989db-f199-4d76-9f89-ea4aca480b27","title":"Improving the validity and translation of preclinical research","_rev":"feQG1v5Q2NahcmQBPTmAlI","_updatedAt":"2022-10-20T09:49:57Z","slug":{"current":"/news/improving-the-validity-and-translation-of-preclinical-re","_type":"slug"},"date":"2022-06-20","seoNoIndex":false,"categories":null,"image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}}},{"_id":"6dedb6f0-5015-4b3c-8834-9b92840b081e","seoNoIndex":false,"_updatedAt":"2022-10-20T10:31:07Z","date":"2022-01-18","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_createdAt":"2022-09-12T15:37:43Z","title":"DevelRx contribute to new publication showing that ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and may have potential for the treatment of substance use disorders","_rev":"Rejt3t5Fpi8uEcdG3YNV7G","richText":[{"markDefs":[],"children":[{"marks":[],"text":"Ulotaront is a novel compound being developed for the treatment of schizophrenia by Sunovion Pharmaceuticals. Unlike all available antipsychotics, it does not block D2 or 5-HT2A-receptors. Its exact mode of action is still unclear but is likely to reflect its activity as a full and partial agonist at trace amine-associated receptor 1 (TAAR1) and 5-HT1A receptors, respectively.","_key":"dc76858b129b0","_type":"span"}],"_type":"block","style":"normal","_key":"012d9ccadfb8"},{"children":[{"_type":"span","marks":[],"text":"A recent publication in Drug and Alcohol Dependence describes the results of a program of non-clinical studies designed to assess the abuse potential of this new drug and to explore its efficacy in behavioural models of substance abuse. Full details of the article are:","_key":"c484833e21f20"}],"_type":"block","style":"normal","_key":"513d409eec8b","markDefs":[]},{"markDefs":[],"children":[{"text":"Syan C, Bowen C, Heal DJ, Froger-Colléaux C, Beardsley PM, Dedic N, Hopkins SC, Campbell U, Koblan KS. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats. Drug and Alcohol Dependence Volume 231, 1 February 2022, 109261.","_key":"a3ca80ba9a910","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"e59f020b43b4"},{"style":"normal","_key":"4f42b9c43f8b","markDefs":[{"_type":"customLink","_key":"e44bbac8b28e","customLink":{"external":"https://doi.org/10.1016/j.drugalcdep.2021.109261","blank":true,"_type":"customUrl"}}],"children":[{"text":"You can read the full article ","_key":"4ce1d220c7580","_type":"span","marks":[]},{"marks":["e44bbac8b28e"],"text":"here","_key":"a0448bc3f515","_type":"span"},{"_key":"2763ccf757bc","_type":"span","marks":[],"text":" "}],"_type":"block"},{"children":[{"marks":[],"text":"DevelRx contributed to this research and one of our Directors, David Heal, is co-author of the paper.","_key":"463a80b082b20","_type":"span"}],"_type":"block","style":"normal","_key":"a31111d53a31","markDefs":[]},{"_key":"aaacd25ddad7","markDefs":[{"_type":"customLink","_key":"6a70324084bf","customLink":{"_type":"customUrl","external":"/contact"}}],"children":[{"_key":"600909db45d80","_type":"span","marks":[],"text":"If you would like to know more about the non-clinical models used to evaluate the abuse potential of centrally-acting drugs with novel modes of action please "},{"_type":"span","marks":["6a70324084bf"],"text":"contact us","_key":"a17118f3eba2"},{"_type":"span","marks":[],"text":".","_key":"b756411f00af"}],"_type":"block","style":"normal"}],"seoEnabled":true,"slug":{"current":"/news/develrx-contribute-to-new-publication-showing-that-ulota","_type":"slug"},"_type":"article","categories":null},{"categories":null,"date":"2022-01-10","slug":{"current":"/news/read-our-comprehensive-review-about-the-development-of-d","_type":"slug"},"seoEnabled":true,"title":"Read our comprehensive review about the development of drugs to treat binge-eating disorder","_createdAt":"2022-09-12T15:36:01Z","_id":"e316f440-fbbf-4865-8144-c27c7c11b35c","_rev":"3Uw8iGh9ict8NFiP8MLHz3","seoNoIndex":false,"_updatedAt":"2022-10-20T14:38:18Z","image":{"asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"},"_type":"image"},"_type":"article","richText":[{"_type":"block","style":"normal","_key":"6fa70a2142ca","markDefs":[],"children":[{"text":"DevelRx are experts in the development of drugs to treat psychiatric disorders. As part of RenaSci, we supported the development of lisdexamfetamine for the treatment of binge-eating disorder (BED). We have recently performed a comprehensive review of all available clinical trials of drugs being developed for this condition. Our findings have been published in the International Journal of Obesity","_key":"9600e0ce1db60","_type":"span","marks":[]}]},{"style":"normal","_key":"432cff4a5bb9","markDefs":[],"children":[{"_key":"5414c5009e220","_type":"span","marks":[],"text":"Heal, D.J., Gosden, J. What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials. Int J Obes 2022 Jan 7"}],"_type":"block"},{"style":"normal","_key":"fe3bc0274146","markDefs":[{"_type":"customLink","_key":"9c4d21bd2ae2","customLink":{"external":"https://rdcu.be/cEuxk","blank":true,"_type":"customUrl"}}],"children":[{"_type":"span","marks":[],"text":"You can read the full article by clicking ","_key":"3e6c063b54990"},{"_type":"span","marks":["9c4d21bd2ae2"],"text":"here","_key":"ab369734b917"},{"_type":"span","marks":[],"text":" ","_key":"1b4113f3cdaa"}],"_type":"block"},{"_type":"block","style":"normal","_key":"63186bd37202","markDefs":[{"_type":"customLink","_key":"9b08b446c694","customLink":{"external":"/contact","blank":false,"_type":"customUrl"}}],"children":[{"_type":"span","marks":[],"text":"Please ","_key":"75b0695431c40"},{"_key":"0981cc7fbbd8","_type":"span","marks":["9b08b446c694"],"text":"contact us"},{"_type":"span","marks":[],"text":" to explore how we can facilitate the development of your new drugs to treat binge-eating disorder.","_key":"dbaf3736f80e"}]}]},{"seoNoIndex":false,"_createdAt":"2022-09-12T15:05:59Z","_type":"article","_updatedAt":"2022-10-20T14:48:19Z","richText":[{"style":"normal","_key":"c86b6c7ba404","markDefs":[{"_type":"customLink","_key":"6dbb84b6cd17","customLink":{"blank":true,"_type":"customUrl","external":"https://www.thecannaconsultants.co.uk/"}}],"children":[{"_type":"span","marks":[],"text":"DevelRx, along with ","_key":"f858cd5e0d620"},{"_type":"span","marks":["6dbb84b6cd17"],"text":"The Canna Consultants","_key":"8722120589c3"},{"_type":"span","marks":[],"text":", a team of experts providing policy and legislation consultancy to governments and regulators on medicinal cannabis and the cannabinoid industry, have recently written to the Food Standards Agency (FSA) and the UK Home Office regarding the scientifically unjustified, and ethically unacceptable, replicate toxicity testing in animals that is being requested by the FSA, on cannabidiol (CBD).","_key":"ec7ae5c6e6db"}],"_type":"block"},{"_key":"dbd85ec3a408","markDefs":[],"children":[{"_type":"span","marks":[],"text":"CBD is a cannabinoid compound, purified from hemp plants, that has been added to a growing number of food products (e.g., oils, tinctures, or confectionary) over the last 2-3 years. These products were brought to the market in the UK and EU and not considered to be subject to regulation. However, in January 2019, CBD was classified as a Novel Food by the EU (and hence UK) and from February 2020, the FSA, acting on guidance from its scientific advisors, the Committee on Toxicology (COT), have requested that manufacturers of food products containing CBD, submit an individual Novel Food application to the FSA for Authorisation of their CBD ingredient and products manufactured from it. This would require for each application, unethical multiple toxicity testing in animals of the same Novel Food product as the different isolates and distillates of CBD have virtually the same chemical composition. Furthermore, CBD has been approved for medical use in humans (Epidyolex; GW Pharmaceuticals) and has already been extensively investigated in both animals and in man. The requirement of the FSA for multiple toxicity testing for CBD is therefore contrary to the principles of the 3R's (reduction, replacement and refinement) to avoid unnecessary use of animals in experiments.","_key":"67ab3b8520670"}],"_type":"block","style":"normal"},{"markDefs":[{"_key":"ab4749bf5baa","customLink":{"external":"https://www.thecannaconsultants.co.uk/cot-evaluation-fsa-testing-demands/","blank":true,"_type":"customUrl"},"_type":"customLink"}],"children":[{"_type":"span","marks":[],"text":"Further information about our challenge to the replicate, toxicity testing demands of the FSA on CBD can be found ","_key":"d18b7280fd810"},{"marks":["ab4749bf5baa"],"text":"here","_key":"4074c4362078","_type":"span"}],"_type":"block","style":"normal","_key":"30b631f9dd53"},{"markDefs":[{"_type":"customLink","_key":"6030e2bcd1e7","customLink":{"external":"https://businesscann.com/","blank":true,"_type":"customUrl"}},{"_key":"326f06c18a4a","customLink":{"external":"https://businesscann.com/flawed-cbd-safety-advice-costs-industry-millions-of-pounds-in-unnecessary-animal-tests/","blank":true,"_type":"customUrl"},"_type":"customLink"}],"children":[{"marks":[],"text":"The issue we raised has been highlighted by ","_key":"15578d3b9c460","_type":"span"},{"_type":"span","marks":["6030e2bcd1e7"],"text":"BusinessCann","_key":"f7fc9911f901"},{"_type":"span","marks":[],"text":", a platform for the cannabinoid industry. See the article ","_key":"319014e3d802"},{"_type":"span","marks":["326f06c18a4a"],"text":"here","_key":"d368b5fd17fe"}],"_type":"block","style":"normal","_key":"71df663dde09"}],"seoEnabled":true,"title":"DevelRx and The Canna Consultants raise concerns about the scientifically unjustified, and ethically unacceptable, replicate toxicity testing of cannabidiol demanded by the Food Standards Agency","date":"2021-12-06","slug":{"_type":"slug","current":"/news/develrx-and-the-canna-consultants-raise-concerns-about-t"},"image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_rev":"3Uw8iGh9ict8NFiP8MRcr7","_id":"3cdf8785-b20b-4a28-b80e-2f3f735fe301","categories":null},{"categories":null,"richText":[{"markDefs":[],"children":[{"marks":[],"text":"We are pleased to announce that Sharon Smith, one of the Directors of DevelRx, has been invited to become a member of the Editorial Board of Neuropharmacology. This reflects her expertise as a psychopharmacologist, her contribution as a Guest Editor of 3 Special Issues of Neuropharmacology (Central Regulation of Food Intake and Energy Expenditure, CNS Stimulants and Psychedelics: New Doors, Altered Perceptions) and her contribution to the journal through published research and reviews.","_key":"e11af6ed0f200","_type":"span"}],"_type":"block","style":"normal","_key":"cf03655e0835"},{"style":"normal","_key":"f4cf619657a6","markDefs":[{"_type":"customLink","_key":"e4d933d321ac","customLink":{"external":"https://www.sciencedirect.com/journal/neuropharmacology/vol/142/suppl/C","blank":true,"_type":"customUrl"}}],"children":[{"marks":[],"text":"Click ","_key":"5d955cf9f77d0","_type":"span"},{"_type":"span","marks":["e4d933d321ac"],"text":"here","_key":"40a2fd2ebb4f"},{"_type":"span","marks":[],"text":" for more information on the Special Issue of Neuropharmacology on Psychedelics: New Doors, Altered Perceptions","_key":"a4710423710c"}],"_type":"block"},{"markDefs":[{"_type":"customLink","_key":"a202acf75036","customLink":{"_type":"customUrl","external":"https://www.sciencedirect.com/journal/neuropharmacology/vol/87","blank":true}}],"children":[{"_type":"span","marks":[],"text":"Click ","_key":"20b8105c89da0"},{"_key":"5dbdecc22bf8","_type":"span","marks":["a202acf75036"],"text":"here"},{"text":" for more information on the Special Issue of Neuropharmacology on CNS Stimulants","_key":"c9ec356a1399","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"2dbdb95a4daf"},{"markDefs":[{"_type":"customLink","_key":"bc6c91610423","customLink":{"external":"https://www.sciencedirect.com/journal/neuropharmacology/vol/63/issue/1","blank":true,"_type":"customUrl"}}],"children":[{"_type":"span","marks":[],"text":"Click ","_key":"58fde73fa5e00"},{"marks":["bc6c91610423"],"text":"here","_key":"c89f5162127d","_type":"span"},{"_type":"span","marks":[],"text":" for more information on the Special Issue of Neuropharmacology on Central Regulation of Food Intake and Energy Expenditure.","_key":"b10fafd52b57"}],"_type":"block","style":"normal","_key":"36e79a205d74"}],"_updatedAt":"2022-10-20T10:50:03Z","_rev":"feQG1v5Q2NahcmQBPU5mHc","_id":"bb646df7-2065-4c52-bda2-b85fdb2da440","slug":{"_type":"slug","current":"/news/sharon-smith-joins-editorial-board-of-neuropharmacology"},"date":"2021-12-06","_createdAt":"2022-09-12T15:00:15Z","image":{"_type":"image","asset":{"_type":"reference","_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png"}},"_type":"article","seoEnabled":true,"seoNoIndex":false,"title":"Sharon Smith joins Editorial Board of Neuropharmacology"},{"title":"We invite you to attend our presentation ‘Psychedelics and CNS Drugs with Novel Mechanisms. Non-clinical Abuse Evaluations to Meet the Challenge’ Continuing Education Course, Virtual SPS Meeting, October 2021","_updatedAt":"2022-10-20T14:56:05Z","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_type":"article","categories":null,"seoNoIndex":false,"date":"2021-09-22","slug":{"current":"/news/we-invite-you-to-attend-our-presentation-'psychedelics-a","_type":"slug"},"_createdAt":"2022-09-12T14:57:38Z","_rev":"kpBOn6QgO9FUtANgil1tN7","_id":"a617c7f4-fbc3-40c7-82a6-e393b6d9251c","richText":[{"markDefs":[],"children":[{"_key":"84ce87f6e82c0","_type":"span","marks":[],"text":"One of our experts, Professor David Heal, will be giving a presentation “Psychedelics and CNS Drugs with Novel Mechanisms. Non-clinical Abuse Evaluations to Meet the Challenge” during a Continuing Education course associated with the Safety Pharmacology Society Virtual Meeting, 4th to 8th October 2021."}],"_type":"block","style":"normal","_key":"39e18b0a52d3"},{"_key":"626f4b305077","markDefs":[],"children":[{"_type":"span","marks":[],"text":"This talk forms part of the CE course ‘CNS Biomarkers of Mood Disorders and Drug Abuse: Where Are We?’ which will take place on Monday 11th October 2021 from 10:00-13:30h EDT (15.00-18.30h BST; 16.00-19.30h CEST).","_key":"0114440540900"}],"_type":"block","style":"normal"},{"_key":"4a1b947a933e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"DevelRx specialises in non-clinical abuse and dependence evaluations of centrally-acting compounds.","_key":"294a8bfa9fca0"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"17fd556af0b8","markDefs":[{"_key":"60156ddca6d1","customLink":{"external":"/contact","blank":false,"_type":"customUrl"},"_type":"customLink"}],"children":[{"_type":"span","marks":[],"text":"Please ","_key":"1b2b56e5a2d00"},{"_type":"span","marks":["60156ddca6d1"],"text":"contact us","_key":"79cd944892dd"},{"_type":"span","marks":[],"text":" for a copy of our presentation and to find out how we can support the development of your psychedelics and CNS drugs with novel mechanisms.","_key":"1b3026fe6b39"}]}],"seoEnabled":true},{"slug":{"current":"/news/the-next-trip-developing-the-second-generation-of-psyche","_type":"slug"},"_id":"de2e0d6f-9b15-4d82-857b-c22b4722e7e6","date":"2021-09-13","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_createdAt":"2022-09-12T14:54:17Z","_rev":"8FY4bwtHg6TsUVnHx96gp6","categories":null,"seoEnabled":true,"_updatedAt":"2022-10-20T10:54:20Z","richText":[{"style":"normal","_key":"927c81456ad6","markDefs":[],"children":[{"marks":[],"text":"DevelRx are pleased to announce a joint podcast with the CRO, Altasciences, 'The Next Trip – Developing the Second Generation of Psychedelics and their Analogs for Targeted Medical Use'.","_key":"dbfbfda37bfd0","_type":"span"}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"In this podcast, which will air on Tuesday 21st September 2021, 10.30 -11.30 am ET, 3.30 - 4.30 pm BST, experts from DevelRx and Altasciences will examine the preclinical, clinical and regulatory challenges facing the development of more efficacious and safer psychedelic drugs.","_key":"cd2c048f2dee0"}],"_type":"block","style":"normal","_key":"74572a2d1691","markDefs":[]},{"_type":"block","style":"normal","_key":"4adba7cbd8f0","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Speakers from DevelRx are: David Heal (Executive Director) and Chris Atterwill (Consultant). Participants from Altasciences are: Beatrice Setnik (CSO), Debra Kelsh (Principal Investigator, Phase I Clinical Development) and Denise Milovan (Neuroscientist, Clinical Neuropsychologist).","_key":"eb928e6f8c860"}]},{"children":[{"_type":"span","marks":[],"text":"You can register for this free podcast ","_key":"5c63ee1b229a0"},{"text":"here","_key":"6518c38261b0","_type":"span","marks":["71a4f2e03599"]}],"_type":"block","style":"normal","_key":"6ec45f0193aa","markDefs":[{"_type":"customLink","_key":"71a4f2e03599","customLink":{"external":"https://www.eventbrite.ca/e/podcast-second-generation-of-psychedelics-for-targeted-medical-use-tickets-170199674809","blank":true,"_type":"customUrl"}}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"DevelRx have worked on psychedelic drugs for many years. Please get in touch to learn more about our expertise in this area and to find out how we can facilitate the development of your novel psychedelic drugs.","_key":"f3ffb9b9ef560"}],"_type":"block","style":"normal","_key":"2949c8406940"}],"seoNoIndex":false,"_type":"article","title":"The Next Trip - Developing the Second Generation of Psychedelics and their Analogs for Targeted Medical Use. Watch our podcast on 21st September 2021"},{"image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_rev":"vl13bj47EwdnRzecWObvl3","seoNoIndex":false,"title":"Congratulations to Cara Therapeutics and Vifor Pharma on the FDA approval of Korsuva","_createdAt":"2022-09-12T14:50:09Z","seoEnabled":true,"_updatedAt":"2022-09-12T14:50:09Z","categories":null,"richText":[{"markDefs":[],"children":[{"marks":[],"text":"DevelRx were privileged to support the registration of Korsuva for the relentless itch of pruritus suffered by chronic kidney disease patients on haemodialysis.","_key":"1c3dd3f5562a0","_type":"span"}],"_type":"block","style":"normal","_key":"8389751c429a"},{"children":[{"_type":"span","marks":[],"text":"Korsuva (difelikefalin) is an injectable kappa opioid receptor agonist that targets the body's peripheral nervous system and offers significant improvements in safety and effectiveness on the current variety of antihistamine treatments used to combat pruritus.","_key":"ffda1060df190"}],"_type":"block","style":"normal","_key":"9a7280569477","markDefs":[]},{"_key":"15ba83586099","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Moderate to severe levels of pruritus affects roughly 40% of the 500,000 chronic kidney disease patients on haemodialysis in the USA. Korsuva will make a significant contribution to reducing the burden of disease in these patients.","_key":"ddf12e05d3130"}],"_type":"block","style":"normal"}],"slug":{"current":"/news/congratulations-to-cara-therapeutics-and-vifor-pharma-on","_type":"slug"},"date":"2021-08-31","_type":"article","_id":"7ea39e58-ed57-4104-ac19-ee6c329aef8b"},{"_rev":"3Uw8iGh9ict8NFiP8MWN2d","title":"What are the prospects for new drugs for binge-eating disorder? ","_type":"article","_id":"0b371280-a758-4d0c-b56a-135dd7fbbd22","richText":[{"children":[{"_type":"span","marks":[],"text":"Download the newly published article by David Heal and Sharon Smith in the Journal of Psychopharmacology for a comprehensive review of potential new treatments for binge-eating disorder ","_key":"7bc2e0c209b00"},{"_type":"span","marks":["20e4c57eac7f"],"text":"here","_key":"f569dd5340ae"},{"marks":[],"text":".","_key":"fe2757ec9785","_type":"span"}],"_type":"block","style":"normal","_key":"6b52fb3b03a4","markDefs":[{"_key":"20e4c57eac7f","customLink":{"external":"https://journals.sagepub.com/doi/10.1177/02698811211032475","blank":true,"_type":"customUrl"},"_type":"customLink"}]},{"_key":"eaf042e1cde9","markDefs":[],"children":[{"_key":"cba91439b7f30","_type":"span","marks":[],"text":"Binge-eating disorder is a common psychiatric condition which has adverse metabolic consequences. With only one drug approved for its treatment, more are needed urgently. The evidence supports the hypothesis that this condition is an impulse control disorder with similarities to ADHD. The most promising areas for new treatments for binge-eating disorder are drugs that augment noradrenergic and dopaminergic neurotransmission and/or those which are effective in ADHD."}],"_type":"block","style":"normal"}],"date":"2021-08-17","categories":null,"_updatedAt":"2022-10-20T15:04:53Z","slug":{"current":"/news/what-are-the-prospects-for-new-drugs-for-binge-eating-di","_type":"slug"},"seoNoIndex":false,"seoEnabled":true,"image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_createdAt":"2022-09-12T14:48:59Z"},{"categories":null,"_rev":"PUjnReaoeP8IpU99fmyp70","_id":"262c7cd4-1d13-424b-810e-a0ae5c520578","seoEnabled":true,"image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_type":"article","seoNoIndex":false,"_updatedAt":"2023-11-13T15:10:31Z","slug":{"current":"/news/develrx-announces-collaboration-with-scitegrity","_type":"slug"},"richText":[{"_type":"block","style":"normal","_key":"cceca6f4f592","markDefs":[{"_type":"customLink","_key":"648035588328","customLink":{"external":"https://www.scitegrity.com/","blank":true,"_type":"customUrl"}}],"children":[{"_type":"span","marks":[],"text":"DevelRx are proud to announce our collaboration with ","_key":"6a6b7beaa2730"},{"_type":"span","marks":["648035588328"],"text":"Scitegrity","_key":"f31cfd2498d3"},{"_type":"span","marks":[],"text":", the developers of Controlled Substances Squared, the computational system trusted by the world’s top pharmaceutical companies, CROs and regulators to accurately and automatically identify if any chemical is considered controlled or regulated in over 28 countries. Our two companies have partnered to allow robust, quantitative and reproducible chemical similarity assessments of new compounds in development to drugs and chemical space with known or likely abuse potential.","_key":"bcf43096a88c"}]}],"title":"DevelRx announces collaboration with Scitegrity","date":"2021-08-01","_createdAt":"2022-09-12T14:47:29Z"},{"slug":{"_type":"slug","current":"/news/does-every-cns-drug-candidate-require-a-program-of-glp-n"},"image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_type":"article","richText":[{"_type":"block","style":"normal","_key":"04859dc9b181","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Does every CNS drug-candidate require a program of GLP non-clinical abuse potential testing?","_key":"c12d2959a2d00"}]},{"children":[{"_key":"750992a4ce680","_type":"span","marks":[],"text":"The short answer to the question is “No”. Although the FDA and EMA will evaluate the abuse and/or dependence potential of all CNS drug-candidates, in some cases they can perform that evaluation without data from GLP non-clinical abuse/dependence tests. A couple of weeks ago, one of our European pharma clients received notification from the FDA granting it a waiver on all non-clinical GLP abuse/dependence testing by the CSS for its CNS\ndrug-candidate. The waiver was given based on a scientific case that DevelRx had prepared, and it is the fourth waiver that we have managed to secure from the FDA."}],"_type":"block","style":"normal","_key":"8ac21571c6cd","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"The scientific assessment we prepared was based on information from multiple sources that provided a solid evidence base to support our client’s proposal for an abuse/dependence GLP testing waiver.","_key":"5008e54fb9320"}],"_type":"block","style":"normal","_key":"c20472fb81f0","markDefs":[]},{"_key":"44df345a1cbd","markDefs":[{"_type":"customLink","_key":"67316cc26ea6","customLink":{"external":"https://cdn.sanity.io/files/9f1xpw6w/production/950526beebfd374c9e7eb7ea90bacaf2cbbde7e9.pdf","_type":"customUrl"}}],"children":[{"_type":"span","marks":["67316cc26ea6"],"text":"Download our flyer here","_key":"9ffd8bd3d8ae0"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"If you believe that your company’s drug-candidate has a good case for a waiver on GLP abuse/dependence testing, or would like us to give you an expert opinion on this question, contact inform@develrx.com","_key":"1dcbcd0d057f0"}],"_type":"block","style":"normal","_key":"ad91145df90a","markDefs":[]}],"date":"2021-06-14","_createdAt":"2022-09-12T14:43:53Z","seoEnabled":true,"seoNoIndex":false,"categories":null,"title":"Does every CNS drug-candidate require a program of GLP non-clinical abuse potential testing?","_rev":"jG41FS4IO5p78AiwRDm5Wm","_id":"50ee0513-f49a-440f-a1b0-d3e46ee279c7","_updatedAt":"2022-09-12T14:46:10Z"},{"_id":"1ccf7983-a636-4b00-9516-3ed35b4227c3","seoEnabled":true,"image":{"asset":{"_type":"reference","_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png"},"_type":"image"},"richText":[{"_type":"block","style":"normal","_key":"059a6e7e005e","markDefs":[],"children":[{"_key":"31375e685bf70","_type":"span","marks":["strong"],"text":"Join us at the 83rd Annual Scientific Virtual Meeting of the CPDD, 21st - 24th June, 2021."}]},{"_key":"ef594ba3d42f","markDefs":[],"children":[{"_type":"span","marks":[],"text":"David Heal has the following presentations at the 83rd Annual Scientific Virtual Meeting of the CPDD, 21st - 24th June, 2021.","_key":"209de640781f0"}],"_type":"block","style":"normal"},{"_key":"c7fb06eab097","markDefs":[],"children":[{"_key":"9335d8ada3f20","_type":"span","marks":["strong"],"text":"Workshop:"},{"_type":"span","marks":[],"text":" Meeting the Challenge of the Psychedelics and CNS Drugs With Novel Mechanisms – Building on the Foundation of the FDA 2017 Guidance on the Assessment of Abuse Potential. David Heal. Refinements and Innovations in Non-clinical Abuse Evaluations. Wednesday 23rd June 2021. 10 am - 11 am Eastern Time.","_key":"9335d8ada3f21"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"text":"Poster W71: ","_key":"822bc70d9efc0","_type":"span","marks":["strong"]},{"_key":"822bc70d9efc1","_type":"span","marks":[],"text":"David Heal, Sharon Smith. Evidence Against the Involvement of Increased Dopamine Signalling in the Abuse Potential of Mu-Opioid Agonists. Virtual Poster Session III: Opiates/Opioids. Wednesday 23rd June 2021. 3 pm - 4 pm Eastern Time."}],"_type":"block","style":"normal","_key":"997cbedd3195"},{"_type":"block","style":"normal","_key":"a8f39bd84dca","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Poster W133: ","_key":"613a6853ef7c0"},{"text":"Sharon Smith, David Heal. Differences in the Relative Contribution of Drug Re-Exposure and Salient Cues in the Reinstatement of Cocaine, Heroin and Nicotine Seeking. Virtual Poster Session III: Polydrug. Wednesday 23rd June 2021. 3 pm - 4 pm Eastern Time.","_key":"613a6853ef7c1","_type":"span","marks":[]}]},{"_type":"block","style":"normal","_key":"422041b38c3a","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Join us virtually at the meeting or contact inform@develrx.com for further information.","_key":"8779b9e986db0"}]}],"_updatedAt":"2022-09-13T09:22:58Z","categories":null,"_rev":"vl13bj47EwdnRzecWRJXmj","_type":"article","slug":{"current":"/news/join-us-at-the-83rd-annual-scientific-virtual-meeting-of","_type":"slug"},"date":"2021-06-07","seoNoIndex":false,"title":"Join us at the 83rd Annual Scientific Virtual Meeting of the CPDD,  21st- 24th June, 2021","_createdAt":"2022-09-12T14:43:13Z"},{"title":"How can non-clinical research inform the clinical development and prescribing of psychedelic drugs?","_updatedAt":"2022-10-20T15:21:04Z","_id":"af1fed32-c722-4f39-a275-c47d267742cf","richText":[{"_type":"block","style":"normal","_key":"41b33d41d29e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"How can non-clinical research inform the clinical development and prescribing of psychedelic drugs?","_key":"93457b25b0520"}]},{"children":[{"_type":"span","marks":[],"text":"Professor David Heal of DevelRx will explore these issues at the Psychedelic Therapeutics and Drug Development Conference, 4th-6th May 2021.","_key":"b71068513b5b0"}],"_type":"block","style":"normal","_key":"29fa8e1c97a7","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"This meeting to be held virtually will bring together the world’s leading scientists to discuss the challenges and opportunities in the research and development of psychedelics for various health conditions and the progress in regulatory approval for various psychedelics.","_key":"b7dccc2af1010"}],"_type":"block","style":"normal","_key":"ccee63970e06","markDefs":[]},{"children":[{"_type":"span","marks":["8ab4fea42192"],"text":"Contact us","_key":"d185ba19b6e7"},{"_key":"6fda60d1ce13","_type":"span","marks":[],"text":" for further information about our services or for a copy of the presentation."}],"_type":"block","style":"normal","_key":"a69d08ef7249","markDefs":[{"_type":"customLink","_key":"8ab4fea42192","customLink":{"external":"\\contact","blank":false,"_type":"customUrl"}}]},{"style":"normal","_key":"7a178499fd06","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"e8ece9e19e43"}],"_type":"block"},{"_key":"a788ce021794","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"fbdef39e7d5f"}],"_type":"block","style":"normal"}],"date":"2021-04-27","_type":"article","seoEnabled":true,"image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_createdAt":"2022-09-12T14:34:03Z","_rev":"kpBOn6QgO9FUtANgil408T","slug":{"current":"/news/how-can-non-clinical-research-inform-the-clinical-develo","_type":"slug"},"seoNoIndex":false,"categories":null},{"_updatedAt":"2022-10-20T11:01:17Z","_id":"0a775daf-51e2-409b-9d3d-36ea2f4a8c72","date":"2021-03-19","image":{"asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"},"_type":"image"},"slug":{"current":"/news/congratulations-to-our-colleague-dr-jo-palandri-on-her-r","_type":"slug"},"seoNoIndex":false,"_type":"article","richText":[{"style":"normal","_key":"0816f6b0bdc0","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Congratulations to our colleague, Dr Jo Palandri, on her recent publication in the Journal of Psychopharmacology!","_key":"a6e81b7a411f0"}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"The research collaboration between Jo Palandri, Prof Sue Wonnacott and Dr Chris Bailey (University of Bath), Prof David Heal and Dr Sharon Smith (DevelRx) was to investigate the role of nicotinic alpha7 receptors in the rewarding and craving effects of opiates.","_key":"b7c129ee1b0f0"}],"_type":"block","style":"normal","_key":"a926ea3cbbc7","markDefs":[]},{"_key":"8225cffe0a59","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Results from Jo’s PhD project describe how hippocampal alpha7 receptors mediate the retrieval reward-associated memories and describe differences between animal models to assess drug liking versus psychological dependence.","_key":"cf0fd65bb3610"}],"_type":"block","style":"normal"},{"_key":"d4ea9f8389f5","markDefs":[{"_type":"customLink","_key":"544133a82e2c","customLink":{"external":"https://journals.sagepub.com/doi/10.1177/0269881121991570","blank":true,"_type":"customUrl"}}],"children":[{"_type":"span","marks":[],"text":"Jo’s research findings are available to download ","_key":"8199dd2884640"},{"_type":"span","marks":["544133a82e2c"],"text":"here.","_key":"a836fe51ccb2"}],"_type":"block","style":"normal"}],"seoEnabled":true,"title":"Congratulations to our colleague, Dr Jo Palandri, on her recent publication in the Journal of Psychopharmacology! ","_createdAt":"2022-09-12T14:34:30Z","categories":null,"_rev":"Rejt3t5Fpi8uEcdG3YT68G"},{"richText":[{"_key":"9f7dd376f703","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"How do we adapt to continue making accurate, experimental-based predictions of drug abuse risks?","_key":"ea783d9c95490"}],"_type":"block","style":"normal"},{"children":[{"_key":"1dcc6a7dfc700","_type":"span","marks":[],"text":"DevelRx takes great pleasure to announce that we will be co-hosting a workshop at the 83rd Annual Scientific Virtual Meeting of the College on Problems of Drug Dependence (CPDD) conference, June 19th - 23rd 2021:"}],"_type":"block","style":"normal","_key":"3d11f6d8e968","markDefs":[]},{"_key":"9e19748adb3d","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"“Meeting the Challenge of the Psychedelics and CNS Drugs with Novel Mechanisms – Building on the Foundation of the FDA 2017 Guidance on the Assessment of Abuse Potential”","_key":"fb1b353d03cd0"}],"_type":"block","style":"normal"},{"children":[{"marks":[],"text":"The workshop will be chaired by Professor David Heal (DevelRx, UK; University of Bath, UK) and Professor Jack Henningfield (Pinney Associates, USA; Johns Hopkins University School of Medicine, USA).","_key":"f6757ceae6d90","_type":"span"}],"_type":"block","style":"normal","_key":"0691716d20b7","markDefs":[]},{"_key":"057caa534316","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Talks addressing the issues will be given by the eminent scientists: Jack Henningfield, David Heal, Professor Charles France (University of Texas Health Science Center at San Antonio, USA) and Dr Judy Ashworth (Pinney Associates, USA),","_key":"693906e243cc0"}],"_type":"block","style":"normal"},{"_key":"51e8508e471e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"This will be a highly interactive forum and is relevant to participants from the pharmaceutical industry, regulatory agencies, healthcare professionals and academia.","_key":"72822a7b03500"}],"_type":"block","style":"normal"},{"style":"normal","_key":"d79387990ba2","markDefs":[],"children":[{"_key":"ac80c2ac02870","_type":"span","marks":[],"text":"Get in touch for further information."}],"_type":"block"}],"_updatedAt":"2022-10-20T14:31:57Z","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"seoEnabled":true,"date":"2021-03-14","_createdAt":"2022-09-12T14:31:03Z","_type":"article","_id":"b746eae7-d7bf-4bf4-b1d7-dd9bf77e6043","title":"How do we adapt to continue making accurate, experimental-based predictions of drug abuse risks? ","categories":null,"_rev":"0EyQcLVRY1ZgNeLqtBJAX2","seoNoIndex":false,"slug":{"current":"/news/how-do-we-adapt-to-continue-making-accurate-experimental","_type":"slug"}},{"_updatedAt":"2022-10-20T10:44:32Z","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"title":"DevelRx was very pleased to assist Always Pure Organics with the preparation of their three dossiers that were submitted to the FSA last month for Cannabidiol (CBD)-based Novel Foods; one for their Swiss Isolate, one for their Colombian Isolate and one for their Colombian Distillate.","date":"2021-03-04","_createdAt":"2022-09-12T14:29:39Z","seoNoIndex":false,"categories":null,"_rev":"Rejt3t5Fpi8uEcdG3YP0Dg","_type":"article","_id":"bc4543f3-a7a3-4a01-a3d5-44c966778be4","seoEnabled":true,"richText":[{"markDefs":[{"_type":"customLink","_key":"33477777adcd","customLink":{"external":"https://www.alwayspureorganics.com/novel-foods-application-has-been-submitted/","blank":true,"_type":"customUrl"}}],"children":[{"_type":"span","marks":[],"text":"DevelRx was very pleased to assist Always Pure Organics with the preparation of their three dossiers that were submitted to the FSA last month for Cannabidiol (CBD)-based Novel Foods; one for their Swiss Isolate, one for their Colombian Isolate and one for their Colombian Distillate.\n\nDevelRx provided the extensive Safety Pharmacology evaluations for the dossier and expert advice with the design of Toxicity studies.\n\nTo read more, please click ","_key":"915eff73646f0"},{"text":"here","_key":"962fcf4ca475","_type":"span","marks":["33477777adcd"]},{"_key":"95d52b4b4b18","_type":"span","marks":[],"text":"\n"}],"_type":"block","style":"normal","_key":"8c431310c959"}],"slug":{"current":"/news/develrx-was-very-pleased-to-assist-always-pure-organics-","_type":"slug"}},{"image":{"asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"},"_type":"image"},"_type":"article","richText":[{"_key":"ed9f553d77c0","markDefs":[],"children":[{"_type":"span","marks":[],"text":"BPS, LASA & Psychiatry Consortium joint workshop: Exploring the Status of Preclinical Models of Psychiatric Disorders - Their Validity and Scope for Successful Translation - 25th February 2021.","_key":"406d18d5e0c50"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"The objective of the BPS (British Pharmacological Society), LASA (Laboratory Animal Science Association) & Psychiatry Consortium joint workshop​ was to explore ideas for refining existing preclinical models of psychiatric disorders to increase their translational validity, expanding their application across multiple domains in complex psychiatric disorders, and to discuss approaches to design novel behavioural models as a means to discover and develop new therapeutics.","_key":"898e17284fe20"}],"_type":"block","style":"normal","_key":"1528ac95728d","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"This interactive workshop was free to attendees and its online format ensured participation of delegates from around the world and by a large number of early-career researchers.​ With a focus on good behavioural science being linked with high animal welfare standards, it also attracted attendance by representatives from the RSPCA and NC3Rs (National Centre for the Replacement, Refinement and Reduction of Animals in Research) as well as the scientific research community.","_key":"6fea2beb7c650"}],"_type":"block","style":"normal","_key":"541275cc74b1","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The presentation given by Professor David Heal who co-chaired the workshop highlighted the role that behavioural science plays not only in identifying new targets for drug discovery, but also as predictors of therapeutic efficacy and as indicators of drug safety and tolerability. DevelRx’s extensive experience and expertise in non-clinical evaluation of abuse and dependence was used to illustrate this point. Safety Pharmacology testing in drug development is critical because data from clinical trials will not serve as a safety net if serious drug-induced adverse events or potential are missed. For this reason, translational validity is an absolute essential.","_key":"f003761dc0640"}],"_type":"block","style":"normal","_key":"3f3fd0dc976f"},{"markDefs":[],"children":[{"marks":[],"text":"The output from this highly successful and over-subscribed workshop will be the subject of a Commentary that will be published in the Journal of Psychopharmacology.","_key":"0eecb26efd520","_type":"span"}],"_type":"block","style":"normal","_key":"6431f834eec6"},{"_key":"4516dab5af0d","markDefs":[{"_key":"221e6436165f","customLink":{"external":"https://cdn.sanity.io/files/9f1xpw6w/production/c4626d2a3a4da8c57c75e73625eccfd27b85aa6e.pdf","blank":true,"_type":"customUrl"},"_type":"customLink"}],"children":[{"marks":["221e6436165f"],"text":"Download the slides here","_key":"ea41a65caf2b0","_type":"span"}],"_type":"block","style":"normal"}],"slug":{"current":"/news/bps-lasa-and-psychiatry-consortium-joint-workshop:-explo","_type":"slug"},"date":"2021-02-25","_id":"118df6d6-faf1-44ed-b640-ccd7e62f7893","title":"BPS, LASA & Psychiatry Consortium joint workshop: Exploring the Status of Preclinical Models of Psychiatric Disorders - Their Validity and Scope for Successful Translation - 25th February 2021","_updatedAt":"2022-10-20T10:08:19Z","_rev":"feQG1v5Q2NahcmQBPTqzas","seoEnabled":true,"seoNoIndex":false,"_createdAt":"2022-09-12T14:20:11Z","categories":null},{"slug":{"current":"/news/develrx-continues-its-medical-education-support-for-psyc","_type":"slug"},"_id":"723a487a-9d27-41d5-b74a-5c833ebdeab9","_createdAt":"2022-09-12T14:17:39Z","richText":[{"children":[{"_type":"span","marks":[],"text":"DevelRx continues its medical education support for psychiatrists and other healthcare providers treating attention deficit hyperactivity disorder. At the invitation of Takeda Pharmaceuticals, David Heal will be presenting a lecture entitled “How can pharmacology help determine treatment choice in ADHD?” at the Dutch Paediatric Society (NVK; Nederlandse Vereniging voor Kindergeneeskunde) Virtual Meeting on Thursday December 17th, 2020, 15.30-16.00h (UK time).","_key":"578d8114f7670"}],"_type":"block","style":"normal","_key":"5df93ea527b1","markDefs":[]}],"seoEnabled":true,"seoNoIndex":false,"title":"DevelRx continues its medical education support for psychiatrists and other healthcare providers treating attention deficit hyperactivity disorder. ","_updatedAt":"2022-10-20T15:24:40Z","date":"2020-12-14","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"_type":"article","_rev":"0EyQcLVRY1ZgNeLqtBhBXf","categories":null},{"_updatedAt":"2022-09-13T09:26:19Z","_createdAt":"2022-09-12T14:14:57Z","_type":"article","seoEnabled":true,"title":"Professor David Heal will be co-presenting two posters at the American College of Neuropsychopharmacology (ACNP) 59th Annual Meeting - Virtual Conference to be held from 6th to 9th December, 2020.","_rev":"IX45xG3BUUPsuElQN8I9if","richText":[{"style":"normal","_key":"1413c5d92e22","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Professor David Heal will be co-presenting two posters at the American College of Neuropsychopharmacology (ACNP) 59th Annual Meeting - Virtual Conference to be held from 6th to 9th December, 2020.","_key":"c4922ceed4450"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The posters report new findings on two late-stage novel drug-candidates: Centafadine, which is Otsuka Pharmaceuticals’ drug-candidate for the treatment of ADHD, and SEP-363856, which is Sunovion Pharmaceuticals’ non-D2, non-5-HT2A drug-candidate for the treatment of schizophrenia.","_key":"4763e6116bd00"}],"_type":"block","style":"normal","_key":"d56e8efa0af1"},{"children":[{"_type":"span","marks":["strong"],"text":"T149","_key":"ba44ffc6a9f20"},{"_type":"span","marks":[],"text":": ","_key":"ba44ffc6a9f21"},{"_type":"span","marks":["strong"],"text":"Poster session II; Tuesday 8th December 2.00 – 3.30 pm (CET) (15.00-16.30h [EST] and","_key":"ba44ffc6a9f22"},{"_type":"span","marks":[],"text":"\n","_key":"ba44ffc6a9f23"},{"marks":["strong"],"text":"20.00-21.30h [UK time]).","_key":"ba44ffc6a9f24","_type":"span"}],"_type":"block","style":"normal","_key":"f3306bf34127","markDefs":[]},{"_key":"d737f62bceb3","markDefs":[],"children":[{"_type":"span","marks":[],"text":"SEP-363856, a Novel TAAR1 Agonist, Lacks Abuse Liability in Preclinical Models and Attenuates Cocaine Cue-Induced Relapse in Rats.","_key":"6d7ddc823a1e0"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Colleen Synan, Carrie Bowen, David Heal, Christelle Froger-Colleaux, Patrick M. Beardsley, Una Campbell.","_key":"ab3682061ee20"}],"_type":"block","style":"normal","_key":"2b20415c4c87"},{"_key":"d7f8114aad93","markDefs":[],"children":[{"_key":"0a129ab8b2660","_type":"span","marks":["strong"],"text":"W51:"},{"_key":"0a129ab8b2661","_type":"span","marks":[],"text":" "},{"_type":"span","marks":["strong"],"text":"Poster session II1; Wednesday 9th December 3.30 – 5.00 pm (CET) (16.30-18.00h [EST] and 21.30-23.00h [UK time]).","_key":"0a129ab8b2662"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Evaluation of the Discriminative and Reinforcing Potential of Centanafadine and Reference Comparator ADHD Drugs by Drug-Discrimination and Intravenous Self-Administration Testing in Rats.","_key":"186836d669e20"}],"_type":"block","style":"normal","_key":"0c329f99bbf0"},{"children":[{"_key":"88e32e69fa7b0","_type":"span","marks":[],"text":"David Heal, Helen Rowley, Sharon Smith, Reem Elbekai."}],"_type":"block","style":"normal","_key":"a2ca6d2a61f5","markDefs":[]}],"slug":{"current":"/news/professor-david-heal-will-be-co-presenting-two-posters-a","_type":"slug"},"image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"categories":null,"_id":"5d315a30-afaf-4879-9f75-6198ab7c0118","seoNoIndex":false,"date":"2020-11-11"},{"seoEnabled":true,"slug":{"current":"/news/professor-david-heal-dr-sharon-smith-and-dr-reem-elbekai","_type":"slug"},"_createdAt":"2022-09-12T14:05:13Z","_rev":"vl13bj47EwdnRzecWRKBQH","_type":"article","seoNoIndex":false,"title":"Professor David Heal, Dr Sharon Smith and Dr Reem Elbekai will be co-presenting two posters on Centanafadine at the American College of Toxicology (ACT) Virtual Meeting (November 12th to 19th 2020). ","_updatedAt":"2022-09-13T09:26:58Z","_id":"14fe7ae2-ffde-466b-8db5-77012601f20c","richText":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Professor David Heal, Dr Sharon Smith and Dr Reem Elbekai will be co-presenting two posters on Centanafadine at the American College of Toxicology (ACT) Virtual Meeting (November 12th to 19th 2020).","_key":"4cbb355727400"}],"_type":"block","style":"normal","_key":"ebc708598f8d"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Centafadine is Otsuka’s drug-candidate that is in late-stage development for the treatment of ADHD and the posters report experimental results from the non-clinical assessment of Centanafadine’s risk for human abuse.","_key":"ae4e9abd76f00"}],"_type":"block","style":"normal","_key":"33014808a788"},{"_type":"block","style":"normal","_key":"3d9a88ac6d9f","markDefs":[],"children":[{"text":"The poster session is scheduled for Monday 16th November at 17.00 – 18.30h (EST) [22.00-23.30h (UK time)].","_key":"09c3133f1bdb0","_type":"span","marks":["strong"]}]},{"markDefs":[],"children":[{"marks":["strong"],"text":"P: 507","_key":"fae4cbaf1be80","_type":"span"}],"_type":"block","style":"normal","_key":"a630481bb7f1"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"An investigation of the reinforcing potential of centanafadine in rats trained to self-administer cocaine.","_key":"b832f57ae5360"}],"_type":"block","style":"normal","_key":"8694ab525f1d"},{"style":"normal","_key":"d1854f844b7e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"David Heal, Sharon Smith, Harriet Day, Zara Turnbull, Reem Elbekai","_key":"12a8ddbe7aee0"}],"_type":"block"},{"style":"normal","_key":"4570d2b06348","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"P: 518","_key":"2df21e4ce4050"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"An investigation of the discriminative properties of centanafadine in rats trained to discriminate d-amphetamine from saline.","_key":"7ad9d21c5f600"}],"_type":"block","style":"normal","_key":"1ea56b2ebd58"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Reem Elbekai, Helen Rowley, David Heal","_key":"30fea78de4b70"}],"_type":"block","style":"normal","_key":"44b8ac997801"}],"categories":null,"date":"2020-11-09","image":{"asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"},"_type":"image"}},{"_rev":"vl13bj47EwdnRzecWRKF9X","seoEnabled":true,"title":"DevelRx is delighted to announce that the University of Bath and DevelRx have agreed to co-sponsor a PhD project entitled “Mu and kappa opioid receptors in addictive behaviour”.","image":{"_type":"image","asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"}},"slug":{"current":"/news/develrx-is-delighted-to-announce-that-the-university-of-","_type":"slug"},"_type":"article","date":"2020-11-01","_createdAt":"2022-09-12T12:25:59Z","_id":"8a0f1701-fd14-422b-8bc0-da1c88436f30","richText":[{"_key":"44af482cb980","markDefs":[],"children":[{"_key":"6b7587931c930","_type":"span","marks":[],"text":"DevelRx is delighted to announce that the University of Bath and DevelRx have agreed to co-sponsor a PhD project entitled “Mu and kappa opioid receptors in addictive behaviour”."}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"4401906b2b70","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The 3.5 year project will be based in the Department of Pharmacy and Pharmacology commencing in September 2020.","_key":"118a1c027d6d0"}]},{"markDefs":[],"children":[{"text":"Co-supervisors on the project are Dr Chris Bailey (Department of Pharmacy and Pharmacology), Prof Sue Wonnacott (Department of Biochemistry) and DrSarah Bailey (Department of Pharmacy and Pharmacology). David Heal is a Visiting Professor in the Department of Pharmacy and Pharmacology at the University of Bath.","_key":"2535c366f3af0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"6f01c5bf6198"}],"seoNoIndex":false,"_updatedAt":"2022-09-13T09:27:21Z","categories":null},{"_rev":"kpBOn6QgO9FUtANgil4UVF","image":{"asset":{"_ref":"image-e8fd69c72455b33c4abd7ad7d320dd48fb366855-1200x630-png","_type":"reference"},"_type":"image"},"_createdAt":"2022-09-12T14:07:00Z","_type":"article","_id":"b34b1f61-0c70-4761-9959-f45f6423b90f","richText":[{"markDefs":[],"children":[{"_key":"10f488bd7e910","_type":"span","marks":[],"text":"David Heal will give a presentation at the American College of Toxicology Virtual Meeting (November 12th to 19th 2020) as part of the Continuing Education Course—CE07 entitled “Understanding the Assessment of Abuse Potential: Industry and Regulatory Perspective”"}],"_type":"block","style":"normal","_key":"300ad3a17414"},{"_key":"14130023d3cb","markDefs":[],"children":[{"_key":"207930196dfd0","_type":"span","marks":[],"text":"The session will be chaired by Dr Reem Elbekai (Otsuka Pharmaceutical Development and Commercialization) and Dr William Brock (Brock Scientific Consulting). The other presenters are Dr Mike Klein, who is the previous Director of the FDA’s Controlled Substance Staff and Dr Dominic Chiapperino, the current Director of CSS, and the clinical expert, Professor Ed Sellers (University of Toronto and DL Global Partners)."}],"_type":"block","style":"normal"},{"style":"normal","_key":"9b0d9d0619ab","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"11:00 AM–11:05 AM","_key":"421dc67b2e650"},{"_type":"span","marks":[],"text":"\n","_key":"421dc67b2e651"},{"text":"Introduction","_key":"421dc67b2e652","_type":"span","marks":["strong"]}],"_type":"block"},{"children":[{"_type":"span","marks":["strong"],"text":"CE07-1 11:05 AM–11:45 AM","_key":"687b03f1813a0"},{"text":"\nPharmacology and Molecular Mechanisms of Drugs of Abuse","_key":"687b03f1813a1","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"122b06ccd399","markDefs":[]},{"markDefs":[],"children":[{"text":"CE07-2 11:45 AM–12:30 PM","_key":"b8e6962b33490","_type":"span","marks":["strong"]},{"text":"\nRole of Abuse Testing in the Development of CNS Drugs\nDavid J. Heal, DevelRx Ltd and University of Bath.","_key":"b8e6962b33491","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"1f27a43681b0"},{"_key":"1af257441b47","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"12:30 PM–1:00 PM","_key":"96747df6ca320"},{"text":"\nBreak","_key":"96747df6ca321","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"CE07-3 1:00 PM–1:40 PM","_key":"9ac2e3d7a36c0"},{"text":"\nConducting a Successful Human Abuse Potential Study and Integration with Other Clinical Data\nEdward Sellers, University of Toronto and DL Global Partners.","_key":"9ac2e3d7a36c1","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"e5c25e981bea"},{"markDefs":[],"children":[{"marks":["strong"],"text":"CE07-4 1:40 PM–2:20 PM","_key":"0a5f95fbde780","_type":"span"},{"text":"\nRegulatory Perspective on Abuse Potential Assessment and the Drug Scheduling Process\nDominic Chiapperino, US Food and Drug Administration, Center for Drug Evaluation and Research","_key":"0a5f95fbde781","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"2e60f659e5f9"},{"_key":"df616e4ae63b","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"2:20 PM–2:30 PM","_key":"4c6ca72c43230"},{"marks":[],"text":"\nQuestions and Answers","_key":"4c6ca72c43231","_type":"span"}],"_type":"block","style":"normal"}],"seoEnabled":true,"slug":{"_type":"slug","current":"/news/david-heal-will-give-a-presentation-at-the-american-coll"},"_updatedAt":"2022-10-20T15:27:01Z","date":"2020-10-11","seoNoIndex":false,"title":"David Heal will give a presentation at the American College of Toxicology Virtual Meeting (November 12th to 19th 2020) as part of the Continuing Education Course—CE07 entitled “Understanding the Assessment of Abuse Potential: Industry and Regulatory Perspective”","categories":null}],"navigation":{"_createdAt":"2022-09-09T12:12:39Z","_rev":"drDVwmdZ7WTxDAuOQzZgBW","_type":"navigation","links":[{"_key":"adb2f240bd61","title":"Home","isDropdown":false,"url":{"external":"/","_type":"customUrl","internal":null},"_type":"navigationTopMenu","navigationItems":null},{"_type":"navigationTopMenu","_key":"2114065b4fcc","title":"Team","navigationItems":null,"isDropdown":false,"url":{"internal":{"slug":{"current":"/team","_type":"slug"}},"_type":"customUrl"}},{"navigationItems":[{"url":{"internal":{"slug":{"current":"/services/research-and-candidate-selection","_type":"slug"}},"_type":"customUrl"},"_type":"navigationItem","_key":"be92fc28ea44","title":"Research & Candidate Selection"},{"_key":"0729f3b1bf72","title":"Drug Development","url":{"internal":{"slug":{"current":"/services/drug-development","_type":"slug"}},"_type":"customUrl"},"_type":"navigationItem"},{"_type":"navigationItem","_key":"10b2492c2bcb","title":"Registration","url":{"internal":{"slug":{"current":"/services/registration","_type":"slug"}},"_type":"customUrl"}},{"_key":"77ac0211405f","title":"Marketing","url":{"internal":{"slug":{"current":"/services/marketing","_type":"slug"}},"_type":"customUrl"},"_type":"navigationItem"}],"_type":"navigationTopMenu","_key":"c024bbe95d58","title":"Services","isDropdown":true,"url":{"external":"/services","_type":"customUrl","internal":null}},{"_type":"navigationTopMenu","_key":"9295fc1ee773","title":"Areas of Expertise","isDropdown":true,"url":{"external":"/area-of-expertise","_type":"customUrl","internal":null},"navigationItems":[{"_type":"navigationItem","_key":"1da8b6d81083","title":"Drug Abuse Evaluation","url":{"_type":"customUrl","internal":{"slug":{"current":"/area-of-expertise/drug-abuse-evaluation","_type":"slug"}}}},{"_type":"navigationItem","_key":"6352041335e50c7e72289581781ec7f5","title":"ADHD","url":{"internal":{"slug":{"_type":"slug","current":"/area-of-expertise/adhd"}},"_type":"customUrl"}},{"_key":"db6aac05289c77a04d34bdc67238b375","title":"Binge-Eating Disorder","url":{"internal":{"slug":{"current":"/area-of-expertise/binge-eating-disorder","_type":"slug"}},"_type":"customUrl"},"_type":"navigationItem"},{"_type":"navigationItem","_key":"5387423b267041eae30a7e0a8ab1b31f","title":"Psychiatric and Neurological Disorders","url":{"internal":{"slug":{"current":"/area-of-expertise/psychiatric-and-neurological-disorders","_type":"slug"}},"_type":"customUrl"}},{"_type":"navigationItem","_key":"f1a5bf5526b731ba1eba2fcbd3cb13d3","title":"Obesity and Metabolic Disorders","url":{"internal":{"slug":{"current":"/area-of-expertise/obesity-and-metabolic-disorders","_type":"slug"}},"_type":"customUrl"}},{"_type":"navigationItem","_key":"02971d495b37","title":"Psychedelics and Cannabinoids","url":{"external":"/area-of-expertise/psychedelics-and-cannabinoids","blank":false,"_type":"customUrl","internal":null}}]},{"url":{"external":"/news","_type":"customUrl","internal":null},"_type":"navigationTopMenu","_key":"84a38f00d981","navigationItems":null,"title":"News","isDropdown":false},{"_type":"navigationTopMenu","_key":"b93a6b306a73","title":"Company Literature","isDropdown":false,"url":{"_type":"customUrl","internal":{"slug":{"current":"/company-literature","_type":"slug"}}},"navigationItems":null},{"navigationItems":[{"_key":"d6ea6cf2c431","title":"Professional Partners","url":{"internal":{"slug":{"_type":"slug","current":"/professional-partners"}},"blank":false,"_type":"customUrl"},"_type":"navigationItem"},{"_type":"navigationItem","_key":"3eda30003276","title":"Academic Partners","url":{"internal":{"slug":{"current":"/academic-partners","_type":"slug"}},"blank":false,"_type":"customUrl"}}],"_type":"navigationTopMenu","_key":"db23277bd387","title":"Partners","isDropdown":true,"url":{"internal":{"slug":{"current":"/professional-partners","_type":"slug"}},"blank":false,"_type":"customUrl"}},{"isDropdown":false,"url":{"internal":{"slug":{"current":"/contact","_type":"slug"}},"_type":"customUrl"},"navigationItems":null,"_type":"navigationTopMenu","_key":"ca740a58018a","title":"Contact"}],"_id":"navigation","_updatedAt":"2023-01-16T12:08:41Z","phone":"+44 (0) 115 787 0500"},"footer":{"_updatedAt":"2022-11-30T13:30:47Z","_createdAt":"2022-09-10T17:05:38Z","_type":"footer","_rev":"A8ZNR3dBsYCnWmpAtMaKy0","richTextRight":[{"_type":"block","style":"normal","_key":"4d10a54b089d","markDefs":[{"_type":"customLink","_key":"f29c59220fdd","customLink":{"_type":"customUrl","external":"mailto:inform@develrx.com"}},{"_type":"customLink","_key":"a79537c51bef","customLink":{"external":"https://www.linkedin.com/company/develrx-ltd/","_type":"customUrl"}}],"children":[{"_type":"span","marks":["f29c59220fdd"],"text":"inform@develrx.com","_key":"0123f141db480"},{"_type":"span","marks":[],"text":"\n","_key":"bf7840f4aa22"},{"text":"Follow us on LinkedIn","_key":"da3f6491d3350","_type":"span","marks":["a79537c51bef"]},{"_key":"78b9acce7015","_type":"span","marks":[],"text":"\nRegistered in England and Wales\nCompany number: 12028847"}]}],"_id":"footer","richText":[{"children":[{"text":"Biocity,\nPennyfoot Street,\nNottingham,\nNottinghamshire,\nNG1 1GF","_key":"45f91f0ca7440","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"d73544f206ee","markDefs":[]}],"footerColumns":[{"_key":"38a310a5f82c","title":"Legal","urls":[{"_type":"footerLink","_key":"54e02b994a58","title":"Privacy Policy","url":{"internal":{"slug":{"_type":"slug","current":"/privacy-policy"}},"_type":"customUrl"}},{"_type":"footerLink","_key":"54d9a7e930e3","title":"Cookie Policy","url":{"internal":{"slug":{"_type":"slug","current":"/cookie-policy"}},"_type":"customUrl"}},{"_type":"footerLink","_key":"f3bd2df5d28a","title":"Terms & Conditions","url":{"internal":{"slug":{"current":"/terms-and-conditions","_type":"slug"}},"_type":"customUrl"}}],"_type":"footerColumn"},{"urls":[{"_key":"c7940b8206b7","title":"Home","url":{"external":"/","_type":"customUrl","internal":null},"_type":"footerLink"},{"url":{"_type":"customUrl","internal":{"slug":{"current":"/team","_type":"slug"}}},"_type":"footerLink","_key":"5520703b9e7d","title":"Team"},{"_type":"footerLink","_key":"f685206d4a5e","title":"Areas of Expertise","url":{"external":"/area-of-expertise","blank":false,"_type":"customUrl","internal":null}},{"title":"Services","url":{"external":"/services","blank":false,"_type":"customUrl","internal":null},"_type":"footerLink","_key":"4a4471d5cedd"},{"_type":"footerLink","_key":"657e9c6a37a0","title":"News","url":{"external":"/news","_type":"customUrl","internal":null}},{"_type":"footerLink","_key":"2a45d32bf685","title":"Company Literature","url":{"blank":false,"_type":"customUrl","external":"/company-literature","internal":null}},{"_type":"footerLink","_key":"56385a4201e9","title":"Professional Partners","url":{"_type":"customUrl","external":"/professional-partners","internal":null}},{"title":"Academic Partners","url":{"external":"/academic-partners","blank":false,"_type":"customUrl","internal":null},"_type":"footerLink","_key":"a1c45f6aa4ee"},{"_type":"footerLink","_key":"7e39a639e33f","title":"Contact","url":{"internal":{"slug":{"_type":"slug","current":"/contact"}},"_type":"customUrl"}}],"_type":"footerColumn","_key":"680cf7b53fe5","title":"Pages"}],"titleRight":"Contact details","title":"Location","pageBuilder":null}}},"__N_SSG":true}